US20030175236A1 - Fat-binding polymers - Google Patents
Fat-binding polymers Download PDFInfo
- Publication number
- US20030175236A1 US20030175236A1 US10/307,151 US30715102A US2003175236A1 US 20030175236 A1 US20030175236 A1 US 20030175236A1 US 30715102 A US30715102 A US 30715102A US 2003175236 A1 US2003175236 A1 US 2003175236A1
- Authority
- US
- United States
- Prior art keywords
- mol
- poly
- polymer
- hcl
- fat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229920000642 polymer Polymers 0.000 title claims abstract description 198
- 230000027455 binding Effects 0.000 title claims abstract description 62
- 238000000034 method Methods 0.000 claims abstract description 61
- 208000008589 Obesity Diseases 0.000 claims abstract description 12
- 235000020824 obesity Nutrition 0.000 claims abstract description 12
- 241000124008 Mammalia Species 0.000 claims abstract description 11
- 238000010521 absorption reaction Methods 0.000 claims abstract description 7
- SIKWOTFNWURSAY-UHFFFAOYSA-N Lipstatin Natural products CCCCCCC1C(CC(CC=CCC=CCCCCC)C(=O)OC(CC(C)C)NC=O)OC1=O SIKWOTFNWURSAY-UHFFFAOYSA-N 0.000 claims abstract description 6
- OQMAKWGYQLJJIA-CUOOPAIESA-N lipstatin Chemical compound CCCCCC[C@H]1[C@H](C[C@H](C\C=C/C\C=C/CCCCC)OC(=O)[C@H](CC(C)C)NC=O)OC1=O OQMAKWGYQLJJIA-CUOOPAIESA-N 0.000 claims abstract description 6
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 claims abstract description 6
- AHLBNYSZXLDEJQ-UHFFFAOYSA-N N-formyl-L-leucylester Natural products CCCCCCCCCCCC(OC(=O)C(CC(C)C)NC=O)CC1OC(=O)C1CCCCCC AHLBNYSZXLDEJQ-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000013367 dietary fats Nutrition 0.000 claims abstract description 5
- 229960001243 orlistat Drugs 0.000 claims abstract description 5
- 230000002209 hydrophobic effect Effects 0.000 claims description 52
- 239000000178 monomer Substances 0.000 claims description 49
- 125000000217 alkyl group Chemical group 0.000 claims description 29
- 229940086609 Lipase inhibitor Drugs 0.000 claims description 16
- 229940127470 Lipase Inhibitors Drugs 0.000 claims description 6
- 125000006165 cyclic alkyl group Chemical group 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 239000004367 Lipase Substances 0.000 abstract description 10
- 102000004882 Lipase Human genes 0.000 abstract description 9
- 108090001060 Lipase Proteins 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 9
- 235000019421 lipase Nutrition 0.000 abstract description 9
- 208000006575 hypertriglyceridemia Diseases 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 4
- 230000029087 digestion Effects 0.000 abstract description 3
- 231100000053 low toxicity Toxicity 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- -1 OLESTRATM Substances 0.000 description 228
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 143
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 120
- 239000000203 mixture Substances 0.000 description 119
- 239000000243 solution Substances 0.000 description 112
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 105
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 90
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 87
- 229920000083 poly(allylamine) Polymers 0.000 description 75
- 239000003925 fat Substances 0.000 description 74
- 235000019197 fats Nutrition 0.000 description 74
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 66
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 57
- 239000000047 product Substances 0.000 description 56
- 239000007787 solid Substances 0.000 description 54
- 238000002360 preparation method Methods 0.000 description 49
- 150000001412 amines Chemical class 0.000 description 45
- 229910052757 nitrogen Inorganic materials 0.000 description 35
- 239000007864 aqueous solution Substances 0.000 description 31
- 239000000843 powder Substances 0.000 description 30
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 29
- 239000000499 gel Substances 0.000 description 25
- 239000000523 sample Substances 0.000 description 23
- TYVWBCMQECJNSK-UHFFFAOYSA-N [2-methyl-3-(2-methylprop-2-enoyloxy)butan-2-yl]azanium;chloride Chemical compound [Cl-].CC([NH3+])(C)C(C)OC(=O)C(C)=C TYVWBCMQECJNSK-UHFFFAOYSA-N 0.000 description 22
- 125000001424 substituent group Chemical group 0.000 description 22
- PBLNBZIONSLZBU-UHFFFAOYSA-N 1-bromododecane Chemical compound CCCCCCCCCCCCBr PBLNBZIONSLZBU-UHFFFAOYSA-N 0.000 description 21
- 229920002873 Polyethylenimine Polymers 0.000 description 20
- 239000008367 deionised water Substances 0.000 description 20
- 229910021641 deionized water Inorganic materials 0.000 description 20
- 238000003756 stirring Methods 0.000 description 20
- MNDIARAMWBIKFW-UHFFFAOYSA-N 1-bromohexane Chemical compound CCCCCCBr MNDIARAMWBIKFW-UHFFFAOYSA-N 0.000 description 19
- 239000012265 solid product Substances 0.000 description 19
- 229910001220 stainless steel Inorganic materials 0.000 description 19
- 239000010935 stainless steel Substances 0.000 description 19
- 239000008187 granular material Substances 0.000 description 18
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 17
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 17
- 239000002244 precipitate Substances 0.000 description 17
- 230000035484 reaction time Effects 0.000 description 17
- 239000002904 solvent Substances 0.000 description 17
- 239000012043 crude product Substances 0.000 description 15
- 238000010908 decantation Methods 0.000 description 15
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 15
- 239000000725 suspension Substances 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 239000002168 alkylating agent Substances 0.000 description 14
- 229940100198 alkylating agent Drugs 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- 229920001577 copolymer Polymers 0.000 description 14
- 150000003839 salts Chemical class 0.000 description 14
- 238000001914 filtration Methods 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 11
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 11
- 239000003431 cross linking reagent Substances 0.000 description 11
- 238000010438 heat treatment Methods 0.000 description 11
- 150000002632 lipids Chemical class 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- WSULSMOGMLRGKU-UHFFFAOYSA-N 1-bromooctadecane Chemical compound CCCCCCCCCCCCCCCCCCBr WSULSMOGMLRGKU-UHFFFAOYSA-N 0.000 description 10
- VMKOFRJSULQZRM-UHFFFAOYSA-N 1-bromooctane Chemical compound CCCCCCCCBr VMKOFRJSULQZRM-UHFFFAOYSA-N 0.000 description 10
- 125000004432 carbon atom Chemical group C* 0.000 description 10
- 235000014113 dietary fatty acids Nutrition 0.000 description 10
- 229930195729 fatty acid Natural products 0.000 description 10
- 239000000194 fatty acid Substances 0.000 description 10
- 150000004665 fatty acids Chemical class 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 125000003118 aryl group Chemical group 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 239000000839 emulsion Substances 0.000 description 9
- LXEKPEMOWBOYRF-UHFFFAOYSA-N [2-[(1-azaniumyl-1-imino-2-methylpropan-2-yl)diazenyl]-2-methylpropanimidoyl]azanium;dichloride Chemical compound Cl.Cl.NC(=N)C(C)(C)N=NC(C)(C)C(N)=N LXEKPEMOWBOYRF-UHFFFAOYSA-N 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 229920006037 cross link polymer Polymers 0.000 description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 8
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical class CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 8
- 238000003828 vacuum filtration Methods 0.000 description 8
- 108050006759 Pancreatic lipases Proteins 0.000 description 7
- 102000019280 Pancreatic lipases Human genes 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical group CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- XKMRRTOUMJRJIA-UHFFFAOYSA-N ammonia nh3 Chemical group N.N XKMRRTOUMJRJIA-UHFFFAOYSA-N 0.000 description 6
- 238000004132 cross linking Methods 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 230000002550 fecal effect Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- PZNOBXVHZYGUEX-UHFFFAOYSA-N n-prop-2-enylprop-2-en-1-amine;hydrochloride Chemical compound Cl.C=CCNCC=C PZNOBXVHZYGUEX-UHFFFAOYSA-N 0.000 description 6
- 230000000269 nucleophilic effect Effects 0.000 description 6
- HMZGPNHSPWNGEP-UHFFFAOYSA-N octadecyl 2-methylprop-2-enoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)C(C)=C HMZGPNHSPWNGEP-UHFFFAOYSA-N 0.000 description 6
- 229920000768 polyamine Polymers 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 206010041969 Steatorrhoea Diseases 0.000 description 5
- 125000002947 alkylene group Chemical group 0.000 description 5
- 125000003710 aryl alkyl group Chemical group 0.000 description 5
- 230000029142 excretion Effects 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000003999 initiator Substances 0.000 description 5
- PBOSTUDLECTMNL-UHFFFAOYSA-N lauryl acrylate Chemical compound CCCCCCCCCCCCOC(=O)C=C PBOSTUDLECTMNL-UHFFFAOYSA-N 0.000 description 5
- FSAJWMJJORKPKS-UHFFFAOYSA-N octadecyl prop-2-enoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)C=C FSAJWMJJORKPKS-UHFFFAOYSA-N 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 0 *OC(C)CC Chemical compound *OC(C)CC 0.000 description 4
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 4
- QYOXLKAKUAASNA-UHFFFAOYSA-N 1-bromodocosane Chemical compound CCCCCCCCCCCCCCCCCCCCCCBr QYOXLKAKUAASNA-UHFFFAOYSA-N 0.000 description 4
- TURITJIWSQEMDB-UHFFFAOYSA-N 2-methyl-n-[(2-methylprop-2-enoylamino)methyl]prop-2-enamide Chemical compound CC(=C)C(=O)NCNC(=O)C(C)=C TURITJIWSQEMDB-UHFFFAOYSA-N 0.000 description 4
- NZWIYPLSXWYKLH-UHFFFAOYSA-N 3-(bromomethyl)heptane Chemical compound CCCCC(CC)CBr NZWIYPLSXWYKLH-UHFFFAOYSA-N 0.000 description 4
- 229920001661 Chitosan Polymers 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- GMSCBRSQMRDRCD-UHFFFAOYSA-N dodecyl 2-methylprop-2-enoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)=C GMSCBRSQMRDRCD-UHFFFAOYSA-N 0.000 description 4
- DLFDEDJIVYYWTB-UHFFFAOYSA-N dodecyl(dimethyl)azanium;bromide Chemical compound Br.CCCCCCCCCCCCN(C)C DLFDEDJIVYYWTB-UHFFFAOYSA-N 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 229940040461 lipase Drugs 0.000 description 4
- 230000004576 lipid-binding Effects 0.000 description 4
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 239000004006 olive oil Substances 0.000 description 4
- 235000008390 olive oil Nutrition 0.000 description 4
- 229940116369 pancreatic lipase Drugs 0.000 description 4
- 208000001162 steatorrhea Diseases 0.000 description 4
- FSSPGSAQUIYDCN-UHFFFAOYSA-N 1,3-Propane sultone Chemical compound O=S1(=O)CCCO1 FSSPGSAQUIYDCN-UHFFFAOYSA-N 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- GIUUCQVKMWBSRT-UHFFFAOYSA-N 2-bromododecane Chemical compound CCCCCCCCCCC(C)Br GIUUCQVKMWBSRT-UHFFFAOYSA-N 0.000 description 3
- OQFSYHWITGFERZ-UHFFFAOYSA-N 2-bromoethanesulfonic acid Chemical compound OS(=O)(=O)CCBr OQFSYHWITGFERZ-UHFFFAOYSA-N 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 3
- 102100031416 Gastric triacylglycerol lipase Human genes 0.000 description 3
- 229920002274 Nalgene Polymers 0.000 description 3
- 229940123066 Polymerase inhibitor Drugs 0.000 description 3
- 238000006640 acetylation reaction Methods 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- SWLVFNYSXGMGBS-UHFFFAOYSA-N ammonium bromide Chemical compound [NH4+].[Br-] SWLVFNYSXGMGBS-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000012062 aqueous buffer Substances 0.000 description 3
- 125000004104 aryloxy group Chemical group 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- UUWSLBWDFJMSFP-UHFFFAOYSA-N bromomethylcyclohexane Chemical compound BrCC1CCCCC1 UUWSLBWDFJMSFP-UHFFFAOYSA-N 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 108010091264 gastric triacylglycerol lipase Proteins 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 239000005297 pyrex Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 3
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229920001059 synthetic polymer Polymers 0.000 description 3
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 2
- MPNXSZJPSVBLHP-UHFFFAOYSA-N 2-chloro-n-phenylpyridine-3-carboxamide Chemical compound ClC1=NC=CC=C1C(=O)NC1=CC=CC=C1 MPNXSZJPSVBLHP-UHFFFAOYSA-N 0.000 description 2
- YPEMKASELPCGPB-UHFFFAOYSA-N 2-methylprop-2-enoic acid;prop-2-enamide Chemical compound NC(=O)C=C.CC(=C)C(O)=O YPEMKASELPCGPB-UHFFFAOYSA-N 0.000 description 2
- KUDUQBURMYMBIJ-UHFFFAOYSA-N 2-prop-2-enoyloxyethyl prop-2-enoate Chemical compound C=CC(=O)OCCOC(=O)C=C KUDUQBURMYMBIJ-UHFFFAOYSA-N 0.000 description 2
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000002830 appetite depressant Substances 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-N hydroperoxyl Chemical compound O[O] OUUQCZGPVNCOIJ-UHFFFAOYSA-N 0.000 description 2
- 125000002346 iodo group Chemical group I* 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 235000015263 low fat diet Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000010907 mechanical stirring Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- DYUWTXWIYMHBQS-UHFFFAOYSA-N n-prop-2-enylprop-2-en-1-amine Chemical compound C=CCNCC=C DYUWTXWIYMHBQS-UHFFFAOYSA-N 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 239000012038 nucleophile Substances 0.000 description 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 125000005208 trialkylammonium group Chemical group 0.000 description 2
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 1
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 1
- TWGBFIWYRWGJCJ-UHFFFAOYSA-M (3-chloro-3-methylbutyl)-methyl-dioctylazanium;bromide Chemical compound [Br-].CCCCCCCC[N+](C)(CCC(C)(C)Cl)CCCCCCCC TWGBFIWYRWGJCJ-UHFFFAOYSA-M 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- MYWOJODOMFBVCB-UHFFFAOYSA-N 1,2,6-trimethylphenanthrene Chemical compound CC1=CC=C2C3=CC(C)=CC=C3C=CC2=C1C MYWOJODOMFBVCB-UHFFFAOYSA-N 0.000 description 1
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
- MYMSJFSOOQERIO-UHFFFAOYSA-N 1-bromodecane Chemical compound CCCCCCCCCCBr MYMSJFSOOQERIO-UHFFFAOYSA-N 0.000 description 1
- VLDPXPPHXDGHEW-UHFFFAOYSA-N 1-chloro-2-dichlorophosphoryloxybenzene Chemical compound ClC1=CC=CC=C1OP(Cl)(Cl)=O VLDPXPPHXDGHEW-UHFFFAOYSA-N 0.000 description 1
- CNDHHGUSRIZDSL-UHFFFAOYSA-N 1-chlorooctane Chemical compound CCCCCCCCCl CNDHHGUSRIZDSL-UHFFFAOYSA-N 0.000 description 1
- RRMRPTOMFGARDV-UHFFFAOYSA-M 12-bromododecyl-decyl-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCBr RRMRPTOMFGARDV-UHFFFAOYSA-M 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- HPILSDOMLLYBQF-UHFFFAOYSA-N 2-[1-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical compound C1OC1COC(CCC)OCC1CO1 HPILSDOMLLYBQF-UHFFFAOYSA-N 0.000 description 1
- BTNZIJNHZRKTDU-UHFFFAOYSA-N 2-methyl-n-[1-(2-methylprop-2-enoylamino)ethyl]prop-2-enamide Chemical compound CC(=C)C(=O)NC(C)NC(=O)C(C)=C BTNZIJNHZRKTDU-UHFFFAOYSA-N 0.000 description 1
- PIYJQTKZHLLZQE-UHFFFAOYSA-N 2-methyl-n-[2-(2-methylprop-2-enoylamino)ethyl]prop-2-enamide Chemical compound CC(=C)C(=O)NCCNC(=O)C(C)=C PIYJQTKZHLLZQE-UHFFFAOYSA-N 0.000 description 1
- VFZKVQVQOMDJEG-UHFFFAOYSA-N 2-prop-2-enoyloxypropyl prop-2-enoate Chemical compound C=CC(=O)OC(C)COC(=O)C=C VFZKVQVQOMDJEG-UHFFFAOYSA-N 0.000 description 1
- KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-vinylpyridine Chemical compound C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- NWUMGKXUOYBUDU-UHFFFAOYSA-M 3-bromobutyl-methyl-dioctylazanium;bromide Chemical compound [Br-].CCCCCCCC[N+](C)(CCC(C)Br)CCCCCCCC NWUMGKXUOYBUDU-UHFFFAOYSA-M 0.000 description 1
- UVKTWFDHGDPIGF-UHFFFAOYSA-N 3-bromopropyl(tridecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCC[NH2+]CCCBr UVKTWFDHGDPIGF-UHFFFAOYSA-N 0.000 description 1
- RYNNSZKWDKFHCL-UHFFFAOYSA-M 3-bromopropyl-dimethyl-octylazanium;bromide Chemical compound [Br-].CCCCCCCC[N+](C)(C)CCCBr RYNNSZKWDKFHCL-UHFFFAOYSA-M 0.000 description 1
- MANIVFOGNGPSKT-UHFFFAOYSA-M 3-bromopropyl-docosyl-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCCCCCC[N+](C)(C)CCCBr MANIVFOGNGPSKT-UHFFFAOYSA-M 0.000 description 1
- YWWLWXAGAFDLHC-UHFFFAOYSA-M 3-bromopropyl-dodecyl-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CCCBr YWWLWXAGAFDLHC-UHFFFAOYSA-M 0.000 description 1
- XCDVWZJDGLZKBZ-UHFFFAOYSA-M 3-chloropropyl-decyl-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCC[N+](C)(C)CCCCl XCDVWZJDGLZKBZ-UHFFFAOYSA-M 0.000 description 1
- WZKCTAJFWYZCBW-UHFFFAOYSA-M 3-chloropropyl-dimethyl-octadecylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCl WZKCTAJFWYZCBW-UHFFFAOYSA-M 0.000 description 1
- FCQSEXGTTIULLO-UHFFFAOYSA-M 3-chloropropyl-dodecyl-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CCCCl FCQSEXGTTIULLO-UHFFFAOYSA-M 0.000 description 1
- XOJWAAUYNWGQAU-UHFFFAOYSA-N 4-(2-methylprop-2-enoyloxy)butyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCCCOC(=O)C(C)=C XOJWAAUYNWGQAU-UHFFFAOYSA-N 0.000 description 1
- YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 description 1
- DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 description 1
- FHQFIPVLPMRBBR-UHFFFAOYSA-M 4-bromobutyl-methyl-dioctylazanium;bromide Chemical compound [Br-].CCCCCCCC[N+](C)(CCCCBr)CCCCCCCC FHQFIPVLPMRBBR-UHFFFAOYSA-M 0.000 description 1
- ACYWYYRQTAEQFS-UHFFFAOYSA-M 4-chlorobutyl-dodecyl-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CCCCCl ACYWYYRQTAEQFS-UHFFFAOYSA-M 0.000 description 1
- CKVTZHQHHIRERG-UHFFFAOYSA-M 4-iodobutyl-methyl-dioctylazanium;bromide Chemical compound [Br-].CCCCCCCC[N+](C)(CCCCI)CCCCCCCC CKVTZHQHHIRERG-UHFFFAOYSA-M 0.000 description 1
- JHWGFJBTMHEZME-UHFFFAOYSA-N 4-prop-2-enoyloxybutyl prop-2-enoate Chemical compound C=CC(=O)OCCCCOC(=O)C=C JHWGFJBTMHEZME-UHFFFAOYSA-N 0.000 description 1
- KNKBZYUINRTEOG-UHFFFAOYSA-M 6-bromohexyl(trimethyl)azanium;bromide Chemical group [Br-].C[N+](C)(C)CCCCCCBr KNKBZYUINRTEOG-UHFFFAOYSA-M 0.000 description 1
- UYBMXSJCNBXOFC-UHFFFAOYSA-M 6-bromohexyl-decyl-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCC[N+](C)(C)CCCCCCBr UYBMXSJCNBXOFC-UHFFFAOYSA-M 0.000 description 1
- BYQRLLPYDSJZCP-UHFFFAOYSA-M 6-bromohexyl-docosyl-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCBr BYQRLLPYDSJZCP-UHFFFAOYSA-M 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- XLDYQTBLOUFNEQ-UHFFFAOYSA-N CC(=C)C(O)=O.NC(=O)C(C)=CCC=C(C)C(N)=O Chemical compound CC(=C)C(O)=O.NC(=O)C(C)=CCC=C(C)C(N)=O XLDYQTBLOUFNEQ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- ZMJBYMUCKBYSCP-CVYQJGLWSA-N Garcinia acid Chemical compound OC(=O)[C@@H](O)[C@](O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-CVYQJGLWSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000000019 Sterol Esterase Human genes 0.000 description 1
- 108010055297 Sterol Esterase Proteins 0.000 description 1
- DAKWPKUUDNSNPN-UHFFFAOYSA-N Trimethylolpropane triacrylate Chemical compound C=CC(=O)OCC(CC)(COC(=O)C=C)COC(=O)C=C DAKWPKUUDNSNPN-UHFFFAOYSA-N 0.000 description 1
- FHLPGTXWCFQMIU-UHFFFAOYSA-N [4-[2-(4-prop-2-enoyloxyphenyl)propan-2-yl]phenyl] prop-2-enoate Chemical compound C=1C=C(OC(=O)C=C)C=CC=1C(C)(C)C1=CC=C(OC(=O)C=C)C=C1 FHLPGTXWCFQMIU-UHFFFAOYSA-N 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000005211 alkyl trimethyl ammonium group Chemical group 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 229940125709 anorectic agent Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- CREXVNNSNOKDHW-UHFFFAOYSA-N azaniumylideneazanide Chemical group N[N] CREXVNNSNOKDHW-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229920005601 base polymer Polymers 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- QUZSUMLPWDHKCJ-UHFFFAOYSA-N bisphenol A dimethacrylate Chemical compound C1=CC(OC(=O)C(=C)C)=CC=C1C(C)(C)C1=CC=C(OC(=O)C(C)=C)C=C1 QUZSUMLPWDHKCJ-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- IRXBNHGNHKNOJI-UHFFFAOYSA-N butanedioyl dichloride Chemical compound ClC(=O)CCC(Cl)=O IRXBNHGNHKNOJI-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- AAQUAAOHFUYIMI-UHFFFAOYSA-M decyl-dimethyl-(oxiran-2-ylmethyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCC[N+](C)(C)CC1CO1 AAQUAAOHFUYIMI-UHFFFAOYSA-M 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229960000632 dexamfetamine Drugs 0.000 description 1
- 229960004597 dexfenfluramine Drugs 0.000 description 1
- 125000004386 diacrylate group Chemical group 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- UBOHYCDBALEWJC-UHFFFAOYSA-M dodecyl-dimethyl-[5-(4-methylphenyl)sulfonylpentyl]azanium;bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CCCCCS(=O)(=O)C1=CC=C(C)C=C1 UBOHYCDBALEWJC-UHFFFAOYSA-M 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- SUPCQIBBMFXVTL-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C(C)=C SUPCQIBBMFXVTL-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Substances CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004136 fatty acid synthesis Effects 0.000 description 1
- 229960001582 fenfluramine Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PFHZIWAVXDSFTB-UHFFFAOYSA-N hibiscusoic acid Natural products OC(=O)C1OC(=O)CC1(O)C(O)=O PFHZIWAVXDSFTB-UHFFFAOYSA-N 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 235000020845 low-calorie diet Nutrition 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- HADJJUAGACHKHO-UHFFFAOYSA-N n-(oxiran-2-ylmethyl)butanamide Chemical compound CCCC(=O)NCC1CO1 HADJJUAGACHKHO-UHFFFAOYSA-N 0.000 description 1
- XKWWQHSAOSKPJC-UHFFFAOYSA-N n-(oxiran-2-ylmethyl)hexanamide Chemical compound CCCCCC(=O)NCC1CO1 XKWWQHSAOSKPJC-UHFFFAOYSA-N 0.000 description 1
- JRRUOOPFYPGMAE-UHFFFAOYSA-N n-[1-(prop-2-enoylamino)ethyl]prop-2-enamide Chemical compound C=CC(=O)NC(C)NC(=O)C=C JRRUOOPFYPGMAE-UHFFFAOYSA-N 0.000 description 1
- AYGYHGXUJBFUJU-UHFFFAOYSA-N n-[2-(prop-2-enoylamino)ethyl]prop-2-enamide Chemical compound C=CC(=O)NCCNC(=O)C=C AYGYHGXUJBFUJU-UHFFFAOYSA-N 0.000 description 1
- UMLARORAEPLXTC-UHFFFAOYSA-N n-ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine;2-methyl-1-phenylpropan-2-amine Chemical compound CC(C)(N)CC1=CC=CC=C1.CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 UMLARORAEPLXTC-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003562 phentermine Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920000184 poly(octadecyl acrylate) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 238000013022 venting Methods 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
Definitions
- Anorectic agents such as dextroamphetamine, the combination of the non-amphetamine drugs phentermine and fenfluramine (“Phen-Fen”) and dexfenfluramine (Redux) alone, are associated with serious side effects.
- Indigestible materials such as OLESTRATM, mineral oil or neopentyl esters (see U.S. Pat. No. 2,962,419) have been proposed as substitutes for dietary fat.
- Garcinia acid and derivatives thereof have been described as treating obesity by interfering with fatty acid synthesis.
- Swellable crosslinked vinyl pyridine resins have been described as appetite suppressants via the mechanism of providing non-nutritive bulk, as in U.S. Pat. No. 2,923,662. Surgical techniques, such as temporary ileal bypass surgery, are employed in extreme cases.
- the present invention relates to a method for treating obesity, a method for reducing the absorption of dietary fat, and a method for treating hypertriglyceridemia in a patient and to particular polymers for use in the methods or in a manufacture of a medicament.
- the methods comprise the step of orally administering to a mammal, such as a human, a therapeutically effective amount of a fat-binding polymer.
- a fat-binding polymer of the invention facilitates the excretion of fat from the body without digestion, with minimal side effects and low toxicity.
- the fat-binding polymers are administered in combination with a therapeutically effective amount of a lipase inhibitor, such as the pancreatic lipase inhibitors described in U.S. Pat. No. 4,598,089 to Hadvary et al.
- a lipase inhibitor such as the pancreatic lipase inhibitors described in U.S. Pat. No. 4,598,089 to Hadvary et al.
- the combination administration can reduce undesirable side effects often encountered when lipase inhibitors, in particular, the pancreatic lipase inhibitors lipstatin and tetrahydrolipstatin are administered alone.
- a serious side effect resulting from the administration of a lipase inhibitor is steatorrhea, or fatty stools.
- the fat-binding polymers of the invention comprise at least one fat-binding region.
- a fat-binding region can include a region having a positive charge, a region which is hydrophobic or a region having a positive charge and which is hydrophobic.
- the fat-binding polymer is an aliphatic polymer selected from the group consisting of polyalkylacrylates, polyacrylamides, polyalkylmethacrylates, polymethacrylamides, poly-N-alkylacrylamides, poly-N-alkylmethacrylamides, substituted derivatives thereof and copolymers thereof.
- the substituted derivatives of the polymers can be characterized by one or more substituents, such as substituted or unsubstituted, saturated or unsaturated alkyl, and substituted or unsubstituted aryl groups.
- Suitable substituents to employ on the alkyl or aryl groups include, but are not limited to, cationic or neutral groups, such as alkoxy, aryl, aryloxy, aralkyl, halogen, amine, and ammonium groups.
- the polymer can be poly(dimethylamino propylacrylamide), poly(trimethylammonium ethylacrylate), poly(trimethylammonium ethyl methacrylate), poly(trimethylammonium propyl acrylamide), poly(dodecyl acrylate), poly(octadecyl acrylate), poly(octadecyl methacrylate) and copolymers thereof.
- the fat binding polymer is a synthetic amine polymer.
- Amine polymers suitable for use in the invention include, but are not limited to, poly(allylamine), polyethyleneimine, poly(vinylamine), poly(diallylamine), and poly(diallylmethylamine).
- the fat-binding polymer is a hydroxyl-containing polymer, for example, poly(vinylalcohol).
- the fat-binding polymer is an amine-containing polymer wherein one or more hydrophobic regions are bound to a portion of the amine nitrogens of the amine polymer. In a particular embodiment, between about 1 and about 60 percent of the amine nitrogens are substituted, preferably between about 1 and about 30 percent.
- the hydrophobic region of the fat-binding polymer can include a hydrophobic moiety, for example, a substituted or unsubstituted, normal, branched or cyclic alkyl group having at least four carbons.
- the hydrophobic moiety is an alkyl group of between about four and thirty carbons.
- the hydrophobic region is a quaternary amine-containing moiety having a terminal hydrophobic substituent.
- Suitable hydrophobic regions which can include a hydrophobic moiety and/or a quaternary amine-containing moiety are described herein and in U.S. Pat. Nos. 5,607,669, 5,679,717 and 5,618,530, the entire contents of which are incorporated herein by reference in their entirety.
- the fat-binding polymer is substituted by a lipase inhibitor such as those described in U.S. Ser. No. 09/005,379 filed on Jan. 9, 1998, and U.S. Ser. No. 09/166,510 entitled “Lipase Inhibiting Polymers” being filed concurrently herewith, the entire contents of which are incorporated herein by reference.
- the polymers of the present invention offer desirable pharmacological properties such as excellent fat binding properties and low toxicity.
- undesirable side effects experienced, such as steatorrhea, when the lipase inhibitors are administered alone can be lessened.
- the invention relates to a method for treating obesity comprising the step of orally administering to a mammal a therapeutically effective amount of one or more fat-binding polymers.
- the fat-binding polymer is administered in combination with a therapeutically effective amount of a lipase inhibitor.
- the invention in another aspect, relates to a method for reducing the absorption of dietary fat comprising the step of orally administering to a mammal a therapeutically effective amount of one or more fat-binding polymers.
- the fat-binding polymer is administered in combination with a therapeutically effective amount of a lipase inhibitor.
- the invention relates to a method for treating hypertriglyceridemia in a mammal comprising the step of orally administering to a mammal a therapeutically effective amount of one or more fat-binding polymers.
- the fat-binding polymer is administered in combination with a therapeutically effective amount of a lipase inhibitor.
- a particular aspect of the invention relates to a method for treating steatorrhea comprising the step of orally administering to a mammal a therapeutically effective amount of a fat-binding polymer.
- the steatorrhea is a result of the administration of a lipase inhibitor.
- the invention also relates to fat-binding polymers useful in the method of the invention.
- Lipases are ubiquitous enzymes which hydrolyze ester bonds in neutral lipids.
- lipases include, but are not limited to, pancreatic and gastric lipases.
- the preferred substrates of lipases are insoluble in water. Lipases exhibit maximal activity in the presence of lipid/water interfaces.
- pancreatic lipase which is the key enzyme of dietary triglyceride absorption, exerts it activity at the water/lipid interface, in conjunction with bile salts and co-lipase.
- Lippase inhibitor refers to compounds which are capable of inhibiting the action of lipases, for example, gastric and pancreatic lipases.
- Lipstatin and its tetrahydro derivative, Tetrahydrolipstatin as described in U.S. Pat. No. 4,598,089 to Hadvary et al., the entire content of which is hereby incorporated by reference, are potent inhibitors of both gastric and pancreatic lipases, as well as cholesterol ester hydrolase.
- Lipstatin is a natural product of microbial origin, and tetrahydrolipstatin is the result of catalytic hydrogenation of lipstatin.
- Panclicins are analogues of Tetrahydrolipstatin (See e.g., Mutoh, M., et al., “Panclicins, Novel Pancreatic Lipase Inhibitors, II. Structural Elucidation,” The Journal of Antibiotics, 47(12): 1376-1384 (1994), the entire content of which is hereby incorporated by reference.)
- Fat-binding polymers are polymers which absorb, bind or otherwise associate with fat thereby inhibiting (partially or completely) fat digestion, hydrolysis, or absorption in the gastrointestinal tract.
- the fat-binding polymers comprise one or more fat-binding regions.
- “Fat-binding regions”, as defined herein can include a positively charged region, a hydrophobic region, or a region which is both positively charged and hydrophobic.
- Fats are solids or liquid oils generally consisting of glycerol esters of fatty acids.
- Sources of fats include both animal and vegetable fats, for example, triglyceride esters of saturated and/or unsaturated fatty acids, free fatty acids, diglycerides, monoglycerides, phospholipids and cholesterol esters are fats, as defined herein.
- polymers can be employed in the invention described herein.
- the polymers are synthetic polymers which can be aliphatic, or aromatic. However, aliphatic and synthetic polymers are preferred.
- a “synthetic polymer”, as that term is employed herein, is a polymer which is not obtainable from a natural source either directly or through aminor derivatization of the naturally occurring form. Further, the polymer can be hydrophobic, hydrophilic or copolymers of hydrophobic and/or hydrophilic monomers.
- the polymers can be manufactured from olefinic or ethylenic monomers (such as vinylalcohol, allylamine or acrylic acid) or condensation polymers.
- the polymers can include polyvinylalcohol, polyvinylamine, poly-N-alkylvinylamine, polyallylamine, poly-N-alkylallylamine, polydiallylamine, poly-N-alkyldiallylamine, polyalkylenimine, other polyamines, polyethers, polyamides, polyacrylic acids, polyalkylacrylates, polyacrylamides, polymethacrylic acids, polyalkylmethacrylates, polymethacrylamides, poly-N-alkylacrylamides, poly-N-alkylmethacrylamides, polystyrene, polyvinylnaphthalene, polyethylvinylbenzene, polyaminostyrene, polyvinylbiphenyl, polyvinylanisole, polyvinylimidazolyl, polyvinylpyridinyl, polydimethylaminomethylstyrene, polytrimethylammonium ethyl me
- the polymers can be further characterized by one or more substituents such as substituents, such as substituted and unsubstituted, saturated or unsaturated alkyl, and substituted or unsubstituted aryl groups.
- substituents such as substituted and unsubstituted, saturated or unsaturated alkyl, and substituted or unsubstituted aryl groups.
- Suitable groups to employ include cationic or neutral groups, such as alkoxy, aryl, aryloxy, aralkyl, halogen, amine, and ammonium groups.
- Particularly preferred polymers include polyalkylacrylates, polyacrylamides, polyalkylmethacrylates, polymethacrylamides, poly-N-alkylacrylamides, poly-N-alkylmethacrylamides and copolymers thereof. These polymers can be further characterized by one or more substituents, such as substituted or unsubstituted, saturated or unsaturated alkyl, and substituted or unsubstituted aryl groups. Suitable substituents include cationic or neutral groups, such as alkoxy, aryl, aryloxy, aralkyl, halogen, amine, and ammonium groups, for example.
- aliphatic amine polymers such as polyallylamine, polydiallylamine, polydiallylmethylamine, polyvinylamine, polyethylenimine.
- the amine polymer comprises one or more hydrophobic regions which are bound to a portion of the amine nitrogens of the amine polymer. In a particular embodiment, between about 1 and about 60 percent of the amine nitrogens are substituted, preferably between about 1 and about 30 percent.
- the hydrophobic region of the fat-binding polymer can include a hydrophobic moiety, for example, a substituted or unsubstituted, normal, branched or cyclic alkyl group having at least four carbons.
- the hydrophobic moiety is an alkyl group of between about four and thirty carbons.
- the hydrophobic region is a quaternary amine-containing moiety having a terminal hydrophobic substituent.
- the fat-binding region comprises a nitrogen, for example, the nitrogen of an amine, capable of possessing a positive charge under conditions present in the gastro-intestinal tract.
- a nitrogen for example, the nitrogen of an amine, capable of possessing a positive charge under conditions present in the gastro-intestinal tract.
- a quaternary amine-containing moiety or the nitrogen of a polyamine.
- the fat-binding polymer is a hydroxyl-containing polymer, for example, poly(vinylalcohol) which can comprise further fat-binding regions.
- the polymer comprises a repeat unit having the formula
- R is a hydrophobic region
- the polymer can be linear or crosslinked.
- Crosslinking can be performed by reacting the copolymer with one or more crosslinking agents having two or more functional groups, such as electrophilic groups, which react with, for example, amine groups to form a covalent bond.
- Crosslinking in this case can occur, for example, via nucleophilic attack of the polymer amino groups on the electrophilic groups. This results in the formation of a bridging unit which links two or more amino nitrogen atoms from different polymer strands.
- Suitable crosslinking agents of this type include compounds having two or more groups selected from among acyl chloride, epoxide, and alkyl-X, wherein X is a suitable leaving group, such as a halo, tosyl or mesyl group.
- X is a suitable leaving group, such as a halo, tosyl or mesyl group.
- Examples of such compounds include, but are not limited to, epichlorohydrin, succinyl dichloride, acryloyl chloride, butanedioldiglycidyl ether, ethanedioldiglycidyl ether, pyromellitic dianhydride, and dihaloalkanes.
- These crosslinking agents are referred to herein as multifunctional crosslinking agents.
- the polymer composition can also be crosslinked by including a multifunctional co-monomer as the crosslinking agent in the polymerization reaction mixture.
- a multifunctional co-monomer can be incorporated into two or more growing polymer chains, thereby crosslinking the chains.
- Suitable multifunctional co-monomers include, but are not limited to, diacrylates, triacrylates, and tetraacrylates, dimethacrylates, diacrylamides, and dimethacrylamides.
- ethylene glycol diacrylate propylene glycol diacrylate, butylene glycol diacrylate, ethylene glycol dimethacrylate, butylene glycol dimethacrylate, methylene bis(methacrylamide), ethylene bis(acrylamide), ethylene bis(methacrylamide), ethylidene bis(acrylamide), ethylidene bis(methacrylamide), pentaerythritol tetraacrylate, trimethylolpropane triacrylate, bisphenol A dimethacrylate, and bisphenol A diacrylate.
- suitable multifunctional monomers include polyvinylarenes, such as divinylbenzene.
- the amount of cross-linking agent is typically between about 0.5 and about 25 weight % based on the combined weight of crosslinking agent and monomers, with 1-20% being preferred.
- the amount of cross-linking agent that is reacted with the polymer, when the crosslinking agent is a multifunctional agent is sufficient to cause between about 0.1 and 20 percent of the nucleophiles present on the monomer, for example, an amine to react with the crosslinking agent. In a preferred embodiment, between about 3 and 15 percent of the nucleophilic sites, for example, amines react with the multifunctional crosslinking agent.
- the hydrophobic region or regions of the fat-binding polymers include but are not limited to, for example, a hydrophobic moiety such as a substituted or unsubstituted, normal, branched or cyclic alkyl group having at least about four carbons.
- a hydrophobic moiety such as an alkyl group of at least four carbons can be bound to the fat-binding polymer, for example, through an amine of the fat-binding polymer.
- a “hydrophobic moiety”, as the term is used herein, is a moiety which, as a separate entity, is more soluble in octanol than water.
- the octyl group (C 8 H 17 ) is hydrophobic because its parent alkane, octane, has greater solubility in octanol than in water.
- the hydrophobic moieties can be a saturated or unsaturated, substituted or unsubstituted hydrocarbon group.
- Such groups include substituted and unsubstituted, normal, branched or cyclic alkyl groups having at least four carbon atoms, substituted or unsubstituted arylalkyl or heteroarylalkyl groups and substituted or unsubstituted aryl or heteroaryl groups.
- the hydrophobic moiety includes an alkyl group of between about four and thirty carbons.
- hydrophobic moieties include the following alkyl groups n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, n-undecyl, n-dodecyl, n-tetradecyl, n-octadecyl, 2-ethylhexyl, 3-propyl-6-methyl decyl and combinations thereof.
- hydrophobic moieties include haloalkyl groups of at least six carbons (e.g., 10-halodecyl), hydroxyalkyl groups of at least six carbons (e.g., 11-hydroxyundecyl), and aralkyl groups (e.g., benzyl).
- the positively charged region or regions of the fat-binding polymers include but are not limited to, for example, an amine nitrogen capable of possessing a positive charge under conditions present in the gastro-intestinal tract and a quaternary amine-containing moiety.
- Suitable quaternary amine-containing moieties include alkyl trialkylammonium groups also referred to as ammonioalkyl groups.
- ammonioalkyl refers to an alkyl group which is substituted by a nitrogen bearing three additional substituents.
- the nitrogen atom is an ammonium nitrogen atom which bears an alkylene substituent, which links the ammonium nitrogen atom to the polymer, and three additional terminal alkyl substituents having from about one to about twenty-four carbons.
- a “terminal substituent” of the quaternary amine-containing moiety is any one of the three substituents on the quaternary amine nitrogen which is not the carbon chain between the polymer backbone and the nitrogen of the quaternary ammonium center.
- the polymer is an amine polymer and the alkylene group links the ammonium nitrogen atom to the nitrogen atom of the polymer. It is to be understood that multiple moieties can be bound to the same amine and/or different amines of the polymer composition.
- the quaternary amine-containing moiety can bear at least one terminal hydrophobic alkyl substituent, such as an alkyl group having between about four and twenty-four carbons, thereby providing both a hydrophobic region and a positively charged region in combination.
- An ammonioalkyl group will further include a negatively charged counterion, such as a conjugate base of a pharmaceutically acceptable acid.
- a negatively charged counterion such as a conjugate base of a pharmaceutically acceptable acid.
- suitable counterions include Cl ⁇ , PO 4 ⁇ , Br ⁇ , CH 3 SO 3 ⁇ , HSO 4 ⁇ , SO 4 2 ⁇ , HCO 3 ⁇ , CO 3 2 ⁇ , acetate, lactate, succinate, propionate, butyrate, ascorbate, citrate, maleate, folate, an amino acid derivative, and a nucleotide.
- Suitable ammonioalkyl groups are of the general formula:
- R 1 , R 2 and R 3 represent an alkyl group, wherein each R 1 -R 3 , independently, is a normal or branched, substituted or unsubstituted alkyl group having a carbon atom chain length of between about one to about twenty-four carbon atoms, n is an integer having a value of two or more and Y is a negatively charged counterion.
- R 1 , R 2 and R 3 are all methyl groups and n is an integer between about 2 and about 12 (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12).
- the alkyl group which provides the alkylene linking group between the polymer, for example, and the amine of the amine-containing monomer or repeat unit, and the ammonium nitrogen of the alkyl trialkylammonium group, is two or more carbon atoms in length.
- alkylene linking groups are ethyl, propyl, butyl, pentyl, hexyl, octyl, and decyl groups.
- suitable quaternary amine-containing moieties include, but are not limited to:
- 12-(trimethylammonio)dodecyl and combinations thereof A particularly preferred amine-containing moiety is a 6-(trimethylammonio)hexyl group.
- quaternary amine-containing moiety and a hydrophobic moiety are present in the same substituent, thereby providing both a positively charged and hydrophobic region in combination.
- the quaternary amine nitrogen or ammonium nitrogen of the quaternary amine-containing moiety is bound to the polymer backbone by an alkylene having two or more carbons.
- at least one of the three terminal substituents (R 1 , R 2 and R 3 ) of the ammonium nitrogen is a hydrophobic alkyl group having from four to about twenty-four carbons.
- the remaining terminal substituents are each independently a normal or branched, substituted or unsubstituted alkyl group having from one to about twenty-four carbons or a hydrogen atom.
- at least two of the three terminal substituents can be hydrophobic alkyl groups having from four to about twenty-four carbons, the remainder having from one to about twenty-four carbons or a hydrogen atom.
- all three of the terminal substituents can be hydrophobic alkyl groups having from six to about twenty-four carbons.
- a “hydrophobic alkyl group”, as that term is employed herein, includes a substituted or unsubstituted alkyl group having from four to about twenty-four carbons and which is hydrophobic, as earlier defined.
- the hydrophobic alkyl group can be, for example, a normal or branched, substituted or unsubstituted alkyl group having from six to about twenty-four carbons.
- quaternary amine-containing moieties which provide both a hydrophobic and quaternary amine-containing substituent, include, but are not limited to:
- quaternary amine-containing moieties include secondary and tertiary analogs, such as 4-(dioctylmethylammonio) 4 -methylbutyl and 4-(dioctylmethylammonio)-4,4-dimethylbutyl.
- the fat-binding polymers of the invention can be formed, for example, by reacting a polymer, which can be linear or crosslinked, with a suitable alkylating agent or by polymerizing an alkylated monomer.
- an “acylating agent”, as that term is employed herein, means a reactant that, when reacted with a monomer or a copolymer characterized by a repeat unit of the invention and having a nucleophilic site capable of reaction with the acylating agent, causes an acyl substituent, in particular a hydrophobic acyl substituent, as described herein, to be covalently bound to one or more of sites on the fat-binding polymer, for example, the amine nitrogen atoms or hydroxyl oxygens of an amine-containing or hydroxyl-containing monomer or polymer, respectively.
- substituents when multiple substituents are employed, they can be bound to the same and/or different nucleophilic sites of the fat-binding polymer, for example, the same and/or different amine nitrogens of an amine-containing fat-binding polymer or hydroxyl oxygen of a hydroxyl-containing polymer.
- Suitable acylating agents are compounds comprising an acyl group or acyl derivative, for example an anhydride.
- the acylating agent is acetic anhydride the nucleophile is modified by addition of an acetyl group.
- Acylating agents suitable for the addition of a hydrophobic moiety contain an acyl group having at least four carbon atoms, which is bonded to a leaving group such as a halo (e.g., chloro, bromo or iodo).
- Activated esters are also suitable acylating agents.
- an “alkylating agent”, as that term is employed herein, means a reactant that, when reacted with a monomer or a copolymer characterized by a repeat unit of the invention and having a nucleophilic site capable of reaction with the alkylating agent, causes a hydrophobic substituent, as described herein, to be covalently bound to one or more of sites on the fat-binding polymer, for example, the amine nitrogen atoms or hydroxyl oxygens of an amine-containing or hydroxyl-containing monomer or polymer, respectively.
- substituents when multiple substituents are employed, they can be bound to the same and/or different nucleophilic sites of the fat-binding polymer, for example, the same and/or different amine nitrogens of an amine-containing fat-binding polymer or hydroxyl oxygen of a hydroxyl-containing polymer.
- Suitable alkylating agents are compounds comprising an alkyl group or alkyl derivative, having at least four carbon atoms, which is bonded to a leaving group such as a halo (e.g., chloro, bromo or iodo), tosylate, mesylate or epoxy group).
- a halo e.g., chloro, bromo or iodo
- tosylate mesylate or epoxy group
- alkyl halides having at least four carbon atoms such as n-hexyl halide, n-heptyl halide, n-octyl halide, n-nonyl halide, n-decyl halide, n-undecyl halide, n-dodecyl halide, n-tetradecyl
- a dihaloalkane that includes an alkyl group of at least four carbons (e.g., a 1,10-dihalodecane); a hydroxyalkyl halide having at least four carbon atoms (e.g., an 11-halo-1-undecanol); an aralkyl halide (e.g., a benzyl halide); an alkyl epoxy ammonium salt having at least six carbons (e.g., glycidylpropyl-trimethylammonium salts) and epoxyalkylamides having at least six carbons (e.g., N-(2,3-epoxypropyl) butyramide or N-(2,3-epoxypropyl) hexanamide).
- a dihaloalkane that includes an alkyl group of at least four carbons (e.g., a 1,10-dihalodecane); a hydroxyalkyl halide having at least four carbon
- Preferred halogen components of the alkyl halides are bromine and chlorine.
- Particularly preferred alkylating agents which, when reacted with the polymer composition, will cause formation of an amine polymer reaction product that includes a first substituent, are 1-bromodecane and 1-chlorooctane.
- alkylating agents which can provide a quaternary amine-containing moiety have the general formula:
- R 1 , R 2 , and R 3 represent an alkyl group, wherein each R independently is a normal or branched, substituted or unsubstituted alkyl group having a carbon atom chain length of between about one to about twenty four carbon atoms,
- n is an integer having a value of two or more
- X is a leaving group as earlier described, and
- Y is a negatively charged counterion.
- the alkylating agent When at least one of the three terminal substituents of the quaternary amine alkylating agent is a hydrophobic alkyl group having from four to about twenty-four carbons, the alkylating agent therefore provides both a hydrophobic moiety and a quaternary amine-containing moiety.
- the alkylene group in this instance is three or more carbon atoms in length.
- quaternary ammonium compounds suitable as alkylating agents include the following:
- alkylating agents include secondary and tertiary analogs, such as (3-bromobutyl)dioctylmethylammonium bromide and (3-chloro-3,3-dimethyl propyl)dioctylmethylammonium bromide.
- alkyl trimethylammonium alkylating agents include alkyl halide trimethylammonium salts, such as:
- (12-balododecyl)trimethylammonium salt and combinations thereof.
- a particularly preferred quaternary amine-containing alkylating agent is (6-bromohexyl)-trimethylammonium bromide.
- the fat-binding polymer can be have a lipase inhibitor covalently bound to the polymer as described in U.S. Ser. No. 09/005,379 filed on Jan. 9, 1998, and U.S. Ser. No. 09/166,510, entitled “Lipase Inhibiting Polymers” being filed concurrently herewith, the entire contents of both of which are incorporated herein by reference.
- the fat-binding polymer can be administered in combination with a lipase inhibitor which is convalently bound to a polymer as described in U.S. Ser. No. 09/005,379 filed on Jan. 9, 1998, and U.S. Ser. No. 09/166,510 entitled “Lipase Inhibiting Polymers” being filed concurrently herewith, the entire contents of which are incorporated herein by reference.
- the terms “therapeutically effective amount” and “therapeutic amount” are synonymous.
- the terms refer to an amount which is sufficient to treat obesity, reduce the absorption of fat or treat hypertriglyceridemia.
- the dosage of fat-binding polymer administered to the patient will vary depending among other things on the weight of the patient and the general health of the patient. The dosage can be determined with regard to established medical practice.
- the amount of fat-binding polymer administered can be in the range of from about 0.01 mg/kg of body weight/day to about 1 g/kg of body weight/day.
- the amount of lipase inhibitor which can be administered in combination with the fat-binding polymers of the invention can be determined with regard to accepted medical practice.
- the fat-binding polymer is administered in combination with a lipase inhibitor, as described herein.
- the term “in combination” in this context includes both simultaneous or sequential administration (either type of compound first) of the fat-binding polymer and lipase inhibitor.
- the fat-binding polymer and lipase inhibitor when used in combination, can be employed together in the same dosage form or in separate dosage forms taken at the same time or within a time period, wherein both the fat-binding polymer and lipase inhibitor are present in a therapeutically effective amount.
- the fat-binding polymers of the invention can be formulated using conventional inert pharmaceutical adjuvant materials into dosage forms which are suitable for oral administration.
- the oral dosage forms include tablets, capsules, suspension, solutions, and the like.
- the identity of the inert adjuvant materials which are used in formulating the fat-binding polymers of the invention will be immediately apparent to persons skilled in the art.
- These adjuvant materials include, for example, gelatin, albumin, lactose, starch, magnesium stearate, preservatives (stabilizers), melting agents, emulsifying agents, salts, and buffers.
- DAA Diallylamine
- the gel was transferred into a 5-liter bucket with 3 liters of deionized water. The mixture was then stirred with an overhead mechanical stirrer until the gel was well dispersed in solution. The pH was then adjusted to ⁇ 1 using concentrated HCl. The mixture was then vacuum filtered through Whatman 541 filter paper. The filtered polymer gel was then collected and purified by suspension into 4 liters of deionized water followed by vacuum filtration through Whatman 541 filter paper. The procedure of suspension into deionized water followed by vacuum filtration was repeated several times until the conductivity of the suspended polymer gel was ⁇ 0.5 mS/cm.
- the polymer gel was transferred into several Pyrex drying trays and placed into a convection oven at 70° C. to dry (24-48 hours).
- the dried solid was ground to a fine powder using a lab mill with stainless steel blades, and was passed through a sieve (50 mesh) to remove large granules.
- the reaction mixture was then poured into a 5-liter beaker containing 2 liters of methanol stirred with an overhead mechanical stirrer. A fine precipitate was observed as this mixture was stirred for 30 minutes.
- the mixture was vacuum filtered through Whatman 541 filter paper, and the clear filtrate was acidified with concentrated HCl (pH ⁇ 1) producing a thick polymer precipitate and a cloudy solution.
- the cloudy methanol solution was decanted away from the crude solid product.
- the precipitate was dissolved in a minimum amount of water (approx. 300 mL) and acidified with concentrated HCl to a pH of ⁇ 2.
- the aqueous polymer solution was then poured with overhead mechanical stirring into a 3-liter beaker containing at least 5 volumes (approx.
- the dried solid was ground to a fine powder using a lab mill with stainless steel blades, and was passed through a sieve (50 mesh) to remove large granules.
- Poly(diallylamine) Hydrochloride (3250 g of 20% aqueous solution, 4.86 mol monomer equivalents) was placed in a 20-liter bucket equipped with an overhead mechanical stirrer. The pH of the solution was brought to 10.6 by the addition of NaOH (50% solution). Epichlorohydrin (2.86 mL, 0.037 mol) was then added to the rapidly stirred solution in one portion at room temperature (19-22° C.). This mixture was stirred at room temperature (19-22° C.) for 20 hours. A viscous solution resulted. Methanol (10 liters) was added, and the pH was adjusted to >11.5 using a 50% NaOH solution. This solution was then filtered to remove insoluble crosslinked polymer.
- the clear filtrate was acidified with concentrated HCl to a pH of ⁇ 2, and the polymer product was precipitated with the addition of a large volume of ethanol.
- the solid was collected by decantation and washed with isopropanol.
- the solid product was then placed in a convection oven at 70° C. to dry (24-48 hours).
- the dried solid was ground to a fine powder using a lab mill with stainless steel blades, and was passed through a sieve (50 mesh) to remove large granules.
- the filtered polymer gel was collected and suspended in 3 liters of fresh methanol.
- the methanol suspension was acidified to a pH of ⁇ 1 with concentrated HCl.
- the mixture was then vacuum filtered through Whatman 541 filter paper.
- the filtered polymer gel was collected and suspended in 4-liters of 2M aqueous NaCl.
- the aqueous suspension was acidified to a pH of ⁇ 1 with concentrated HCl.
- the mixture was then vacuum filtered through Whatman 541 filter paper.
- the filtered polymer gel was then collected and purified by suspension into 4 liters of deionized water followed by vacuum filtration through Whatman 541 filter paper.
- Acetic anhydride (15.41 g, 0.151 mol) was then added to the stirred solution in one portion. This mixture was stirred at 15° C. for 30 minutes. The solution pH was maintained at 9.5 during this time by the addition of small quantities of 50% NaOH. After the 30 minutes it was observed that the pH of the mixture was stable.
- the crude polymer product was then purified by suspension into 4 liters of deionized water followed by vacuum filtration through Whatman 541 filter paper. The procedure of suspension into deionized water followed by vacuum filtration was repeated several times until the conductivity of the suspended polymer gel was ⁇ 1 mS/cm.
- the polymer gel was then suspended in deionized water (2 liters) and the mixture was acidified with concentrated HCl to a pH of ⁇ 2.5. The mixture was then filtered and transferred into several Pyrex drying trays. The trays were placed into a convection oven at 70° C. to dry (24-48 hours). The dried solid was ground to a fine powder using a lab mill with stainless steel blades, and was passed through a sieve (50 mesh) to remove large granules. The ground product was then placed in a vacuum oven at 60° C. and 28 mmHg for at least 16 hours.
- Poly(allylamine) Hydrochloride 200 g of 50% aqueous solution, 1.07 mol monomer equivalents was dissolved a mixture of ethanol (213 mL) and water (125 mL), and was heated to 70° C. in a 1-liter, round-bottomed flask equipped with an overhead mechanical stirrer, a condenser, and a thermocouple probe. The pH of the solution was brought to 10.0-10.2 by the addition of NaOH (50% solution). 1-Bromododecane (26.66 g, 0.107 mol) was then added to the stirred solution in one portion. This mixture was stirred at 70° C. for 20 hours.
- the solution pH was checked periodically during this time, and was maintained at 10.0-10.2 by the addition of small quantities of 50% NaOH. After the 20 hour reaction time had elapsed, the mixture was cooled to room temperature and the pH was adjusted to 11.5-12.0 by the addition of a 50% NaOH solution. The reaction mixture was then poured into a 5-liter beaker containing 2 liters of methanol stirred with an overhead mechanical stirrer. A fine precipitate was observed as this mixture was stirred for 30 minutes. The mixture was vacuum filtered through Whatman 541 filter paper, and the clear filtrate was acidified with concentrated HCl (pH ⁇ 1) producing a thick polymer precipitate and a cloudy solution. The cloudy methanol solution was decanted away from the crude solid product.
- the precipitate was dissolved in a minimum amount of water (approx. 300 mL) and acidified with concentrated HCl to a pH of ⁇ 2.
- the aqueous polymer solution was then poured with overhead mechanical stirring into a 3-liter beaker containing at least 5 volumes (approx. 1.5 liters) of methanol (isopropanol can be used in place of methanol in this step).
- the polymeric product precipitated as a white solid.
- the precipitate was separated from solution by decantation and suspended in 2 liters of isopropyl alcohol. The solid was broken up using a metal spatula and the mixture was stirred for 2 hours.
- Example 82 The procedure of Example 82 was used. The 50% aqueous solution of poly(allylamine)HCl was replaced with an equivalent amount of a 50% aqueous solution of the polymer product of Example 14. In place of the 1-bromododecane, 1-bromohexane (17.66 g, 0.107 mol) was used.
- Example 82 The procedure of Example 82 was used. The 50% aqueous solution of poly(allylamine)HCl was replaced with an equivalent amount of a 50% aqueous solution of the polymer product of Example 14.
- Example 82 The procedure of Example 82 was used. The 50% aqueous solution of poly(allylamine)HCl was replaced with an equivalent amount of a 50% aqueous solution of the polymer product of Example 14. In place of the 1-bromododecane, 1-bromooctadecane (7.13 g, 0.021 mol) was used.
- Example 82 The procedure of Example 82 was used. The amount of dodecyl bromide used was 67.3 g, 0.27 mol. The 50% aqueous solution of poly(allylamine)HCl was replaced with an equivalent amount of a 50% aqueous solution of the polymer product of Example 14.
- the solution pH was checked periodically during this time, and was maintained at 10.0-10.2 by the addition of small quantities of 50% NaOH. After the 20 hour reaction time had elapsed, the mixture was cooled to room temperature and the pH was adjusted to 11.5-12.0 by the addition of a 50% NaOH solution. The reaction mixture was then poured into a 5-liter beaker containing 2 liters of methanol stirred with an overhead mechanical stirrer. In this case, no precipitate was formed. The methanol solution was evaporated to dryness giving a stick solid. The solid was dissolved in 800 mL of methanol and 3 liters of hexane was added to precipitate the polymer.
- the polymeric solid was washed with an additional 1 liter of hexane and collected by filtration.
- the solid product was placed in a convection oven at 70° C. to dry (24-48 hours).
- the dried solid was ground to a fine powder using a lab mill with stainless steel blades, and was passed through a sieve (50 mesh) to remove large granules.
- the solution pH was checked periodically during this time, and was maintained at 10.0-10.2 by the addition of small quantities of 50% NaOH. After the 20 hour reaction time had elapsed, the mixture was cooled to room temperature giving a white suspension of polymer. The white solid was allowed to settle, and the solution was decanted away. Deionized water (1.5 liters) was added and the slurry was stirred for 15 minutes. The solid was allowed to settle and the solution was removed by decantation. The solid was then dissolved in 800 mL of isopropanol. Concentrated HCl (120 mL) was added but no precipitate was seen. Hexane (3 liters) was added and a white solid precipitated from solution.
- the polymeric solid was washed with an additional 1.5 liters of hexane and collected by filtration.
- the solid product was placed in a convection oven at 70° C. to dry (24-48 hours).
- the dried solid was ground to a fine powder using a lab mill with stainless steel blades, and was passed through a sieve (50 mesh) to remove large granules.
- the solution pH was checked periodically during this time, and was maintained at 10.0-10.2 by the addition of small quantities of 50% NaOH. After the 20 hour reaction time had elapsed, the mixture was cooled to room temperature and the pH was adjusted to 11.5-12.0 by the addition of a 50% NaOH solution. The reaction mixture was then poured into a 5-liter beaker containing 2 liters of methanol stirred with an overhead mechanical stirrer. A fine precipitate was observed as this mixture was stirred for 30 minutes. The mixture was vacuum filtered through Whatman 541 filter paper, and the clear filtrate was acidified with concentrated HCl (pH ⁇ 1) producing a thick polymer precipitate and a cloudy solution. The cloudy methanol solution was decanted away from the crude solid product.
- the solution pH was checked periodically during this time, and was maintained at 10.0-10.2 by the addition of small quantities of 50% NaOH. After the 20 hour reaction time had elapsed, the mixture was cooled to room temperature and poured into a 5-liter beaker containing 2 liters of methanol stirred with an overhead mechanical stirrer. The mixture was acidified with concentrated HCl (pH ⁇ 1) producing a thick polymer precipitate. The methanol solution was decanted away from the crude solid product, and water (approx. 300 mL) was added to disperse the polymeric product into a slurry. Methanol (900 mL) was added giving a dense precipitate.
- the solution was decanted away and the polymer was slurried in water a second time and precipitated with methanol.
- the solid polymer was then washed with 2.5 liters of isopropanol, and then with 1 liter of diethyl ether.
- the solid product was then placed in a convection oven at 70° C. to dry (24-48 hours).
- the dried solid was ground to a fine powder using a lab mill with stainless steel blades, and was passed through a sieve (50 mesh) to remove large granules.
- the mixture was cooled to room temperature and poured into a 20-liter bucket containing 3 liters of methanol stirred with an overhead mechanical stirrer.
- the mixture was acidified with concentrated HCl (pH ⁇ 2), but no precipitate was formed.
- Isopropanol (6 liters) was added, giving a small amount of precipitate.
- Diethyl ether was then added (3 liters) and the crude product precipitated. The solvent was decanted away from the product.
- the crude product was then redispersed in 750 mL of deionized water. The pH was adjusted to ⁇ 2 using concentrated HCl. Acetonitrile (5 liters) was then added to precipitate the polymer.
- the mixture was cooled to room temperature and poured into a 20-liter bucket containing 2 liters of methanol stirred with an overhead mechanical stirrer.
- the mixture was acidified with concentrated HCl (pH ⁇ 2), but no precipitate was formed.
- Diethyl ether was then added (3 liters) and the crude product precipitated.
- the solvent was decanted away from the product.
- the crude product was then redispersed in ethanol (3 liters).
- the pH was adjusted to >11.5 using concentrated NaOH.
- the free base polymer dissolved, leaving a suspension of salts.
- the mixture was vacuum filtered through Whatman 541 filter paper, and the clear filtrate was acidified with concentrated HCl (pH ⁇ 1).
- the mixture was cooled to room temperature and poured into a 20-liter bucket containing 2 liters of methanol stirred with an overhead mechanical stirrer.
- the mixture was acidified with concentrated HCl (pH ⁇ 2), resulting in the precipitation of some polymer.
- Isopropanol was then added (3 liters) and the crude product precipitated.
- the solvent was decanted away from the product.
- the crude product was then redispersed in water (750 mL) and methanol (400 mL) and the pH was adjusted to ⁇ 2 using concentrated HCl. Isopropanol (6 liters) was then added to precipitate the product, which was collected by decantation.
- the solid product was then placed in a convection oven at 70° C. to dry (24-48 hours).
- the dried solid was ground to a fine powder using a lab mill with stainless steel blades, and was passed through a sieve (50 mesh) to remove large granules.
- the mixture was cooled to room temperature and poured into a 20-liter bucket containing 2 liters of methanol stirred with an overhead mechanical stirrer.
- the mixture was acidified with concentrated HCl (pH ⁇ 2), resulting in the precipitation of some polymer.
- Isopropanol was then added (3 liters) and the crude product precipitated.
- the solvent was decanted away from the product.
- the crude product was then redispersed in water (750 mL) and methanol (400 mL) and the pH was adjusted to ⁇ 2 using concentrated HCl. Isopropanol (6 liters) was then added to precipitate the product, which was collected by decantation.
- the solid product was then placed in a convection oven at 70° C. to dry (24-48 hours).
- the dried solid was ground to a fine powder using a lab mill with stainless steel blades, and was passed through a sieve (50 mesh) to remove large granules.
- the mixture was cooled to room temperature and poured into a 20-liter pail containing 5 liters of ethanol stirred with an overhead mechanical stirrer.
- the mixture was acidified with concentrated HCl (pH ⁇ 2), resulting in the precipitation of the crude product.
- the solvent was decanted, and the crude product was then redissolved in water (750 mL).
- the pH was adjusted to ⁇ 2 using concentrated HCl.
- Isopropanol (6 liters) was then added to precipitate the product, which was collected by decantation.
- the solid product was then placed in a convection oven at 70° C. to dry (24-48 hours).
- the dried solid was ground to a fine powder using a lab mill with stainless steel blades, and was passed through a sieve (50 mesh) to remove large granules.
- the mixture was cooled to room temperature and poured into a 20-liter bucket containing 3.5 liters of methanol stirred with an overhead mechanical stirrer.
- the mixture was acidified with concentrated HCl (pH ⁇ 2), resulting in the precipitation of the crude product.
- the solvent was decanted, and the crude product was then redissolved in water (1100 mL).
- the pH was adjusted to ⁇ 2 using concentrated HCl.
- Isopropanol (6 liters) was then added to precipitate the product, which was collected by decantation.
- the solid was washed with another 2 liters of clean isopropanol and collected by decantation.
- the solid product was then placed in a convection oven at 70° C.
- the mixture was cooled to room temperature and poured into a 20-liter bucket containing 2.4 liters of ethanol stirred with an overhead mechanical stirrer.
- the mixture was acidified with concentrated HCl (pH ⁇ 2), resulting in the precipitation the crude product.
- the solvent was decanted, and the crude product was then redissolved in water (700 mL).
- the pH was adjusted to ⁇ 2 using concentrated HCl.
- Isopropanol (6 liters) was then added to precipitate the product, which was collected by decantation.
- the solid was washed with another 2 liters of clean isopropanol and collected by decantation.
- the solid product was then placed in a convection oven at 70° C.
- the solid polymer was then washed with clean isopropanol (2 liters).
- the solid product was then placed in a convection oven at 70° C. to dry (24-48 hours).
- the dried solid was ground to a fine powder using a lab mill with stainless steel blades, and was passed through a sieve (50 mesh) to remove large granules.
- Example 104 The procedure of Example 104 was used. The amount of 1-bromohexane used was 3.72 g, 0.023 mol.
- TMAEAC trimethylaminoethyl acrylchloride quaternary salt
- TMAEAC trimethylaminoethyl acrylchloride quaternary salt
- TMAEAC trimethylaminoethyl acrylchloride quaternary salt
- reaction mixture was allowed to cool to room temperature and poured into a beaker containing isopropanol (1 liter).
- the polymer was precipitated out as a white solid, which was collected and ground to small pieces in a blender using isopropanol as a solvent. The pieces were collected by filtration and the polymer was dried under vacuum at 60° C. for 2 days. The material was ground to a fine powder (80 g), which was used for the in vitro and in vivo studies.
- TMAEAC trimethylaminoethyl acrylchloride quaternary salt
- reaction mixture was purged with nitrogen for 10 min before the addition of a radical initiator, AIBN (330 mg, 2 mmoles).
- AIBN 330 mg, 2 mmoles
- the mixture was heated to 70° C. for 16 hours.
- reaction mixture was allowed to cool to room temperature and poured into a beaker containing isopropanol (1 liter).
- the polymer was precipitated out as a white solid, which was collected and ground to small pieces in a blender using isopropanol as a solvent.
- the pieces were collected by filtration and the polymer was dried under vacuum at 60° C. for 2 days.
- the material was ground to a fine powder (84 g), which was used for the in vitro and in vivo studies.
- TMAEAC trimethylaminoethyl acrylchloride quaternary salt
- the mixture was purged with nitrogen for 10 min before the addition of a radical initiator, AIBN (330 mg, 2 mmoles).
- AIBN 330 mg, 2 mmoles
- the reaction mixture was allowed to cool to room temperature and poured into a beaker containing isopropanol (1 liter).
- the polymer was precipitated out as a white solid, which was collected and ground to small pieces in a blender using isopropanol as a solvent.
- the pieces were collected by filtration and the polymer was dried under vacuum at 60° C. for 2 days.
- the material was ground to a fine powder (80 g), which was used for the in vitro and in vivo studies.
- the following cross-linked polymers were prepared.
- TMAEMC trimethylammonioethyl methacrylate chloride
- Nitrogen was allowed to bubble through the room temperature monomer mixture for at least 20 minutes before adding 0.275 g AIBN [2,2′-azobis(2-methyl-propionitrile)]. At this point the nitrogen was set to blanket the mixture and the heat was turned on to 70° C. The reaction was allowed to heat for 22 hours at 70° C. While the polymer was still warm it was poured from the flask into a Nalgene bucket and allowed to stand for at least three hours in each of four 1-liter washings of isopropanol. Once the polymer became slightly rigid/rubbery it was broken up into small chunks using a blender (with isopropanol as the liquid).
- TMAEMC trimethylammonioethyl methacrylate chloride
- Nitrogen was allowed to bubble through the room temperature monomer mixture for at least 20 minutes before adding 0.275 g AIBN [2,2′-azobis(2-methyl-propionitrile)]. At this point, the nitrogen was set to blanket the mixture and the heat was turned on to 70° C. The reaction was allowed to heat for 22 hours at 70° C. While the polymer was still warm it was poured from the flask into a Nalgene bucket and allowed to stand for at least three hours in each of four 1-liter washings of isopropanol. Once the polymer became slightly rigid/rubbery it was broken up into small chunks using a blender (with isopropanol as the liquid).
- the granular product was filtered and washed with more isopropanol and placed in a crystallizing dish in a 70° C. convection oven for two days. After this time, the product was removed and ground to a fine powder using a grinder and placed back in the oven for two more days.
- GPC analysis of dodecyl methacrylate containing polymers shows MW ranges form 170-190K with polydispersities ranging from 2.3-2.8. Table 10 gives general mole percent compositions of polymers prepared in this fashion.
- TMAEMC trimethylammonioethyl methacrylate chloride
- methacrylamide 9.29 g, 109.29 mmol
- ethanol 300 mL
- the total amount of monomer solids should be 100 g. Nitrogen was allowed to bubble through the room temperature monomer mixture for at least 20 minutes before adding 0.275 g AIBN [2,2′-azobis(2-methyl-propionitrile)].
- TMAEMC trimethylammonioethyl methacrylate chloride
- octadecyl methacrylate 3.65 g, 10.80 mmol
- methacrylamide 9.16 g, 107.76 mmol
- ethanol 400 mL
- the total amount of monomer solids should be 100 g.
- N,N′-methylenebismethacrylamide (1.96 g, 10.76 mmol).
- Nitrogen was allowed to bubble through the room temperature monomer mixture for at least 20 minutes before adding 0.275 g AIBN [2,2′-azobis(2-methyl-propionitrile)]. At this point, the nitrogen was set to blanket the mixture and the heat was turned on to 70° C. Once the polymer began to gel the stirring was turned off; total heating time at 70° C. was approximately 5 hours. The polymer was then allowed cool down to room temperature and stand overnight. The gelled product was scooped out of the flask and swollen to a clear gel in a 500 mL isopropanol/1000 mL water mixture.
- the gel was washed 6 ⁇ with 1000 mL isopropanol filtering over a 50-mesh sieve. Once the polymer became slightly rigid/rubbery it was broken up into small chunks using a blender (with isopropanol as the liquid). The product was filtered over a sieve, wrung out, and placed in a drying dish in a 70° C. convection oven for two days. After this time, the product was removed and ground to a fine powder using a grinder and placed back in the oven for two more days in a glass crystallizing dish. Table 12 gives general mole percent compositions of polymers prepared in this fashion.
- TMAEMC trimethylammonioethyl methacrylate chloride
- aqueous solution 83.97 g, 404.86 mmol
- dodecyl methacrylate (6.85 g, 26.96 mmol)
- methacrylamide 9.18 g, 108.0 mmol
- ethanol 400 mL
- the total amount of monomer solids should be 100 g.
- N,N′-methylenebismethacrylamide (1.96 g, 10.79 mmol).
- Nitrogen was allowed to bubble through the room temperature monomer mixture for at least 20 minutes before adding 0.275 g AIBN [2,2′-azobis(2-methyl-propionitrile)]. At this point, the nitrogen was set to blanket the mixture and the heat was turned on to 70° C. Once the polymer began to gel the stirring was turned off; total heating time at 70° C. was approximately 5 hours. The polymer was then allowed cool down to room temperature and stand overnight. The gelled product was scooped out of the flask and swollen to a clear gel in a 500 mL isopropanol/1000 mL water mixture. The gel was washed 6 ⁇ with 1000 mL of isopropanol filtering over a 50-mesh sieve.
- TMAEMC trimethylammonioethyl methacrylate chloride
- Nitrogen was allowed to bubble through the room temperature monomer mixture for at least 20 minutes before adding 0.275 g AIBN [2,2′-azobis(2-methyl-propionitrile)]. At this point, the nitrogen was set to blanket the mixture and the heat was turned on to 70° C. Once the polymer began to gel the stirring is turned off; total heating time at 70° C. was approximately 5 hours. The polymer was then allowed cool down to room temperature and stand overnight. The gelled product was scooped out of the flask and swollen to a clear gel in a 500 mL isopropanol/1000 mL of water mixture. The gel was washed 6 ⁇ with 1000 mL isopropanol filtering over a 50-mesh sieve.
- the sodium salts of the following bile acids were then added to the flask: glycocholic 1.217 g (2.496 mmol), taurocholic 0.895 g (1.664 mmol), glycodeoxycholic 1.766 g (3.744 mmol), taurodeoxycholic 1.302 g (2.496 mmol).
- the olive oil emulsion described above (15 mL) was then added to the filter cup using an analytical pipette.
- the cap was replaced, and the centrifuge tube shaken (250 rpm) on an orbital mixer for a period of one hour.
- the centrifuge filter device was then disassembled so that the tape could be removed from the bottom of the centrifuge filter cup. It was immediately reassembled and spun in a centrifuge at an RCF of 500 G, and at 25° C. for 30 minutes.
- the centrifuge filter device was removed from the centrifuge and disassembled.
- the filter cup was weighed to obtain the weight gain of the wet polymer/lipid complex. This material was the removed from the filter cup with a spatula, and placed into a tared glass vial.
- the vial was weighed again to obtain the weight of the polymer/lipid sample.
- the vial was then placed into a centrifugal evaporator, and dried at 60° C. under vacuum until a pressure of 0.15 Torr or less was achieved (8-18 hrs).
- the vial was removed and weighed to obtain the dry weight of the polymer/lipid complex sample.
- the amount of lipid absorbed by the original 25 mg polymer sample in the filter cup was then calculated. This gravimetric result was used as a measure for lipid binding by the polymer, and is listed in the accompanying table as lipid weight absorbed (g) per gram of polymer. TABLE 15 Lipid weight (g) absorbed EXAMPLE No.
- Rat fecal samples were collected on the final three days of the six days of drug treatment. The samples were freeze dried and ground to a fine powder. One half gram of sample was weighed and transferred to extraction cells. Samples were extracted in an accelerated solvent extractor (ASE 200 Accelerated Solvent Extractor, Dyonex Corporation, Sunnyvale, Calif.) with 95% ethanol, 5% water and 100 mM KOH. The sample was extracted in 17 minutes at 150° C. and 1500 psi. An aliquot of extract was transferred to a test tube containing a molar excess of HCl.
- ASE 200 Accelerated Solvent Extractor Dyonex Corporation, Sunnyvale, Calif.
- the sample was then evaporated and reconstituted in a detergent solution consisting of 2% Triton X-1200, 1% polyoxyethylene lauryl ether and 0.9% NaCl. Fatty acids were then quantitated enzymatically with a colorimetric kit (NEFAC, Wako Chemical GmbH, Neuss, Germany).
- Table 16 contains values for fecal fat excretion as a percentage of ingested fat. TABLE 16 IN VIVO EFFICACY OF FAT-BINDING POLYMERS FECAL FAT Dose EXCRETION % (w/w percent OF INGESTED Example Identification of diet) FAT Example 6-PAA 3% XL, 5 40 10% C12 Example 6-PAA 3% XL, 10% C12 2 12 Example 5-PAA 9.4% XL 2 22 Example 10-PDA 4.5% XL 2 30 Example 72-PDA 4.5% XL, 11% C12 2 29 Example 173-TMAEMC (90 mol %) + 2 20 octadecyl methacrylate(10 mol %) Chitosan 2 8
- Fecal Fat/Consumed Fat was calculated as follows: Fatty acid concentration from the enzymatic assay was expressed as mmol/mL. The mmol/mL of fatty acid was then multiplied by the number of mL of extract generated from 500 mg of sample to give the total mmol of fatty acid. The value for the total mmol of fatty acid was converted to total mg of fatty acid using the average molecular weight of medium to long chain fatty acid (270 D). The value was corrected for any dilutions made during sample workup. When results are expressed as mg/gm of feces, the total mg of fatty acids is multiplied by 2.
- results were expressed as total mg of fatty acid excreted in 24 hours, the mg/gm of feces value was multiplied by fecal weight in grams excreted in 24 hours.
- results were expressed as excreted fat as a % of that consumed in 24 hours, the total weight of fat excreted in 24 hours was divided by the weight of fatty acids consumed over 24 hours and multiplied by 100.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a method for treating obesity, a method for reducing the absorption of dietary fat, and a method for treating hypertriglyceridemia in a patient and to particular polymers for use in the methods or in a manufacture of a medicament. The methods comprise the step of orally administering to a mammal, such as a human, a therapeutically effective amount of one or more fat-binding polymers. The administration of the fat-binding polymer of the invention facilitates the removal of fat from the body prior to digestion, with minimal side effects and low toxicity. In a preferred embodiment, the one or more fat-binding polymers are administered in combination with one or more lipase inibitors, for example, lipstatin and tetrahydrolipstatin.
Description
- This application is a Continuation of U.S. application Ser. No. 09/721,309, filed Nov. 22, 2000, which is a Divisional of U.S. application Ser. No. 09/166,453, filed Oct. 5, 1998, which is a Continuation-in-Part of U.S. application Ser. No. 09/004,963 filed on Jan. 9, 1998, the entire content of which is hereby incorporated by reference.
- Human obesity is a recognized health problem with approximately 97 million people considered clinically overweight in the United States. The accumulation or maintenance of body fat bears a direct relationship to caloric intake. Therefore, one of the most common methods for weight control to combat obesity is the use of relatively low-fat, low calorie diets, that is, diets containing less fat and calories than a “normal diet” or that amount generally consumed by the patient.
- The presence of fats in a great many food sources greatly limits the food sources which can be used in a low-fat diet. Additionally, fats contribute to the flavor, appearance and physical characteristics of many foodstuffs. As such, the acceptability of low-fat diets and the maintenance of such diets are difficult.
- Various chemical approaches have been proposed for controlling obesity. Anorectic agents, such as dextroamphetamine, the combination of the non-amphetamine drugs phentermine and fenfluramine (“Phen-Fen”) and dexfenfluramine (Redux) alone, are associated with serious side effects. Indigestible materials such as OLESTRA™, mineral oil or neopentyl esters (see U.S. Pat. No. 2,962,419) have been proposed as substitutes for dietary fat. Garcinia acid and derivatives thereof have been described as treating obesity by interfering with fatty acid synthesis. Swellable crosslinked vinyl pyridine resins have been described as appetite suppressants via the mechanism of providing non-nutritive bulk, as in U.S. Pat. No. 2,923,662. Surgical techniques, such as temporary ileal bypass surgery, are employed in extreme cases.
- However, methods for treating obesity, such as those described above, have serious shortcomings with controlled diet remaining the most prevalent technique for controlling obesity. As such, new methods for treating obesity are needed.
- The present invention relates to a method for treating obesity, a method for reducing the absorption of dietary fat, and a method for treating hypertriglyceridemia in a patient and to particular polymers for use in the methods or in a manufacture of a medicament. The methods comprise the step of orally administering to a mammal, such as a human, a therapeutically effective amount of a fat-binding polymer. The administration of a fat-binding polymer of the invention facilitates the excretion of fat from the body without digestion, with minimal side effects and low toxicity. In a preferred embodiment, the fat-binding polymers are administered in combination with a therapeutically effective amount of a lipase inhibitor, such as the pancreatic lipase inhibitors described in U.S. Pat. No. 4,598,089 to Hadvary et al. The combination administration can reduce undesirable side effects often encountered when lipase inhibitors, in particular, the pancreatic lipase inhibitors lipstatin and tetrahydrolipstatin are administered alone. For example, a serious side effect resulting from the administration of a lipase inhibitor is steatorrhea, or fatty stools.
- The fat-binding polymers of the invention comprise at least one fat-binding region. A fat-binding region can include a region having a positive charge, a region which is hydrophobic or a region having a positive charge and which is hydrophobic.
- In one embodiment, the fat-binding polymer is an aliphatic polymer selected from the group consisting of polyalkylacrylates, polyacrylamides, polyalkylmethacrylates, polymethacrylamides, poly-N-alkylacrylamides, poly-N-alkylmethacrylamides, substituted derivatives thereof and copolymers thereof. For example, the substituted derivatives of the polymers can be characterized by one or more substituents, such as substituted or unsubstituted, saturated or unsaturated alkyl, and substituted or unsubstituted aryl groups. Suitable substituents to employ on the alkyl or aryl groups include, but are not limited to, cationic or neutral groups, such as alkoxy, aryl, aryloxy, aralkyl, halogen, amine, and ammonium groups. For example, the polymer can be poly(dimethylamino propylacrylamide), poly(trimethylammonium ethylacrylate), poly(trimethylammonium ethyl methacrylate), poly(trimethylammonium propyl acrylamide), poly(dodecyl acrylate), poly(octadecyl acrylate), poly(octadecyl methacrylate) and copolymers thereof.
- In another embodiment, the fat binding polymer is a synthetic amine polymer. Amine polymers suitable for use in the invention include, but are not limited to, poly(allylamine), polyethyleneimine, poly(vinylamine), poly(diallylamine), and poly(diallylmethylamine).
- In yet another embodiment, the fat-binding polymer is a hydroxyl-containing polymer, for example, poly(vinylalcohol).
- In a specific embodiment, the fat-binding polymer is an amine-containing polymer wherein one or more hydrophobic regions are bound to a portion of the amine nitrogens of the amine polymer. In a particular embodiment, between about 1 and about 60 percent of the amine nitrogens are substituted, preferably between about 1 and about 30 percent.
- In another embodiment, the hydrophobic region of the fat-binding polymer can include a hydrophobic moiety, for example, a substituted or unsubstituted, normal, branched or cyclic alkyl group having at least four carbons. In a particular embodiment, the hydrophobic moiety is an alkyl group of between about four and thirty carbons.
- In another embodiment, the hydrophobic region is a quaternary amine-containing moiety having a terminal hydrophobic substituent. Suitable hydrophobic regions which can include a hydrophobic moiety and/or a quaternary amine-containing moiety are described herein and in U.S. Pat. Nos. 5,607,669, 5,679,717 and 5,618,530, the entire contents of which are incorporated herein by reference in their entirety.
- In yet another embodiment, the fat-binding polymer is substituted by a lipase inhibitor such as those described in U.S. Ser. No. 09/005,379 filed on Jan. 9, 1998, and U.S. Ser. No. 09/166,510 entitled “Lipase Inhibiting Polymers” being filed concurrently herewith, the entire contents of which are incorporated herein by reference.
- The polymers of the present invention offer desirable pharmacological properties such as excellent fat binding properties and low toxicity. In addition, when the fat-binding polymers are administered in combination with lipase inhibitors, as described herein, undesirable side effects experienced, such as steatorrhea, when the lipase inhibitors are administered alone can be lessened.
- The features and other details of the invention will now be more particularly described and pointed out below as well as in the claims. It will be understood that the particular embodiments of the invention are shown by way of illustration and not as limitations of the invention. The principle features of this invention can be employed in various embodiments without departing from the scope of the invention.
- In one aspect, the invention relates to a method for treating obesity comprising the step of orally administering to a mammal a therapeutically effective amount of one or more fat-binding polymers. In a preferred embodiment, the fat-binding polymer is administered in combination with a therapeutically effective amount of a lipase inhibitor.
- In another aspect, the invention relates to a method for reducing the absorption of dietary fat comprising the step of orally administering to a mammal a therapeutically effective amount of one or more fat-binding polymers. In a preferred embodiment, the fat-binding polymer is administered in combination with a therapeutically effective amount of a lipase inhibitor.
- In yet another aspect, the invention relates to a method for treating hypertriglyceridemia in a mammal comprising the step of orally administering to a mammal a therapeutically effective amount of one or more fat-binding polymers. In a preferred embodiment, the fat-binding polymer is administered in combination with a therapeutically effective amount of a lipase inhibitor.
- A particular aspect of the invention relates to a method for treating steatorrhea comprising the step of orally administering to a mammal a therapeutically effective amount of a fat-binding polymer. In a specific embodiment, the steatorrhea is a result of the administration of a lipase inhibitor.
- The invention also relates to fat-binding polymers useful in the method of the invention.
- “Lipases” as that term is used herein, are ubiquitous enzymes which hydrolyze ester bonds in neutral lipids. Examples of lipases include, but are not limited to, pancreatic and gastric lipases. The preferred substrates of lipases are insoluble in water. Lipases exhibit maximal activity in the presence of lipid/water interfaces. For example, pancreatic lipase, which is the key enzyme of dietary triglyceride absorption, exerts it activity at the water/lipid interface, in conjunction with bile salts and co-lipase.
- “Lipase inhibitor” as that term is used herein refers to compounds which are capable of inhibiting the action of lipases, for example, gastric and pancreatic lipases. Lipstatin and its tetrahydro derivative, Tetrahydrolipstatin, as described in U.S. Pat. No. 4,598,089 to Hadvary et al., the entire content of which is hereby incorporated by reference, are potent inhibitors of both gastric and pancreatic lipases, as well as cholesterol ester hydrolase. Lipstatin is a natural product of microbial origin, and tetrahydrolipstatin is the result of catalytic hydrogenation of lipstatin. Other lipase inhibitors include a class of compound commonly referred to as Panclicins. Panclicins are analogues of Tetrahydrolipstatin (See e.g., Mutoh, M., et al., “Panclicins, Novel Pancreatic Lipase Inhibitors, II. Structural Elucidation,” The Journal of Antibiotics, 47(12): 1376-1384 (1994), the entire content of which is hereby incorporated by reference.)
- “Fat-binding polymers”, as that term is used herein, are polymers which absorb, bind or otherwise associate with fat thereby inhibiting (partially or completely) fat digestion, hydrolysis, or absorption in the gastrointestinal tract. The fat-binding polymers comprise one or more fat-binding regions. “Fat-binding regions”, as defined herein can include a positively charged region, a hydrophobic region, or a region which is both positively charged and hydrophobic.
- “Fats”, as that term is used herein, are solids or liquid oils generally consisting of glycerol esters of fatty acids. Sources of fats include both animal and vegetable fats, for example, triglyceride esters of saturated and/or unsaturated fatty acids, free fatty acids, diglycerides, monoglycerides, phospholipids and cholesterol esters are fats, as defined herein.
- A variety of polymers can be employed in the invention described herein. The polymers are synthetic polymers which can be aliphatic, or aromatic. However, aliphatic and synthetic polymers are preferred. A “synthetic polymer”, as that term is employed herein, is a polymer which is not obtainable from a natural source either directly or through aminor derivatization of the naturally occurring form. Further, the polymer can be hydrophobic, hydrophilic or copolymers of hydrophobic and/or hydrophilic monomers. The polymers can be manufactured from olefinic or ethylenic monomers (such as vinylalcohol, allylamine or acrylic acid) or condensation polymers.
- For example, the polymers can include polyvinylalcohol, polyvinylamine, poly-N-alkylvinylamine, polyallylamine, poly-N-alkylallylamine, polydiallylamine, poly-N-alkyldiallylamine, polyalkylenimine, other polyamines, polyethers, polyamides, polyacrylic acids, polyalkylacrylates, polyacrylamides, polymethacrylic acids, polyalkylmethacrylates, polymethacrylamides, poly-N-alkylacrylamides, poly-N-alkylmethacrylamides, polystyrene, polyvinylnaphthalene, polyethylvinylbenzene, polyaminostyrene, polyvinylbiphenyl, polyvinylanisole, polyvinylimidazolyl, polyvinylpyridinyl, polydimethylaminomethylstyrene, polytrimethylammonium ethyl methacrylate, polytrimethylammonium ethyl acrylate, and substituted derivatives of the above (e.g., fluorinated monomers thereof) and copolymers thereof. In addition, the polymers can be further characterized by one or more substituents such as substituents, such as substituted and unsubstituted, saturated or unsaturated alkyl, and substituted or unsubstituted aryl groups. Suitable groups to employ include cationic or neutral groups, such as alkoxy, aryl, aryloxy, aralkyl, halogen, amine, and ammonium groups.
- Particularly preferred polymers include polyalkylacrylates, polyacrylamides, polyalkylmethacrylates, polymethacrylamides, poly-N-alkylacrylamides, poly-N-alkylmethacrylamides and copolymers thereof. These polymers can be further characterized by one or more substituents, such as substituted or unsubstituted, saturated or unsaturated alkyl, and substituted or unsubstituted aryl groups. Suitable substituents include cationic or neutral groups, such as alkoxy, aryl, aryloxy, aralkyl, halogen, amine, and ammonium groups, for example.
- Other particularly preferred polymers include aliphatic amine polymers, such as polyallylamine, polydiallylamine, polydiallylmethylamine, polyvinylamine, polyethylenimine. In a specific embodiment, the amine polymer comprises one or more hydrophobic regions which are bound to a portion of the amine nitrogens of the amine polymer. In a particular embodiment, between about 1 and about 60 percent of the amine nitrogens are substituted, preferably between about 1 and about 30 percent.
- In one embodiment, the hydrophobic region of the fat-binding polymer can include a hydrophobic moiety, for example, a substituted or unsubstituted, normal, branched or cyclic alkyl group having at least four carbons. In a specific embodiment, the hydrophobic moiety is an alkyl group of between about four and thirty carbons.
- In another embodiment, the hydrophobic region is a quaternary amine-containing moiety having a terminal hydrophobic substituent.
- In yet another embodiment, the fat-binding region comprises a nitrogen, for example, the nitrogen of an amine, capable of possessing a positive charge under conditions present in the gastro-intestinal tract. For example, a quaternary amine-containing moiety, or the nitrogen of a polyamine.
-
- wherein R is a hydrophobic region.
- Other polymers and methods of preparation, which can be used in the claimed invention have been reported in the patent literature in, for example, U.S. Pat. Nos. 5,487,888, 5496,545, 5,607,669, 5,618,530, 5,624,963, 5,667,775, and 5,679,717 and co-pending U.S. applications having Ser. Nos. 08/471,747, 08/482,969, 08/567,933, 08/659,264, 08/823,699, 08/835,857, 08/470,940, 08/461,298, 08/826,197, 08/777,408, 08/927,247, 08/964,956, 08/964,498, and 08/964,536, the entire contents of all of which are incorporated herein by reference.
- The polymer can be linear or crosslinked. Crosslinking can be performed by reacting the copolymer with one or more crosslinking agents having two or more functional groups, such as electrophilic groups, which react with, for example, amine groups to form a covalent bond. Crosslinking in this case can occur, for example, via nucleophilic attack of the polymer amino groups on the electrophilic groups. This results in the formation of a bridging unit which links two or more amino nitrogen atoms from different polymer strands. Suitable crosslinking agents of this type include compounds having two or more groups selected from among acyl chloride, epoxide, and alkyl-X, wherein X is a suitable leaving group, such as a halo, tosyl or mesyl group. Examples of such compounds include, but are not limited to, epichlorohydrin, succinyl dichloride, acryloyl chloride, butanedioldiglycidyl ether, ethanedioldiglycidyl ether, pyromellitic dianhydride, and dihaloalkanes. These crosslinking agents are referred to herein as multifunctional crosslinking agents.
- The polymer composition can also be crosslinked by including a multifunctional co-monomer as the crosslinking agent in the polymerization reaction mixture. A multifunctional co-monomer can be incorporated into two or more growing polymer chains, thereby crosslinking the chains. Suitable multifunctional co-monomers include, but are not limited to, diacrylates, triacrylates, and tetraacrylates, dimethacrylates, diacrylamides, and dimethacrylamides. Specific examples include ethylene glycol diacrylate, propylene glycol diacrylate, butylene glycol diacrylate, ethylene glycol dimethacrylate, butylene glycol dimethacrylate, methylene bis(methacrylamide), ethylene bis(acrylamide), ethylene bis(methacrylamide), ethylidene bis(acrylamide), ethylidene bis(methacrylamide), pentaerythritol tetraacrylate, trimethylolpropane triacrylate, bisphenol A dimethacrylate, and bisphenol A diacrylate. Other suitable multifunctional monomers include polyvinylarenes, such as divinylbenzene.
- The amount of cross-linking agent is typically between about 0.5 and about 25 weight % based on the combined weight of crosslinking agent and monomers, with 1-20% being preferred. Typically, the amount of cross-linking agent that is reacted with the polymer, when the crosslinking agent is a multifunctional agent, is sufficient to cause between about 0.1 and 20 percent of the nucleophiles present on the monomer, for example, an amine to react with the crosslinking agent. In a preferred embodiment, between about 3 and 15 percent of the nucleophilic sites, for example, amines react with the multifunctional crosslinking agent.
- The hydrophobic region or regions of the fat-binding polymers include but are not limited to, for example, a hydrophobic moiety such as a substituted or unsubstituted, normal, branched or cyclic alkyl group having at least about four carbons. For example, a hydrophobic moiety such as an alkyl group of at least four carbons can be bound to the fat-binding polymer, for example, through an amine of the fat-binding polymer.
- A “hydrophobic moiety”, as the term is used herein, is a moiety which, as a separate entity, is more soluble in octanol than water. For example, the octyl group (C 8H17) is hydrophobic because its parent alkane, octane, has greater solubility in octanol than in water. The hydrophobic moieties can be a saturated or unsaturated, substituted or unsubstituted hydrocarbon group. Such groups include substituted and unsubstituted, normal, branched or cyclic alkyl groups having at least four carbon atoms, substituted or unsubstituted arylalkyl or heteroarylalkyl groups and substituted or unsubstituted aryl or heteroaryl groups. Preferably, the hydrophobic moiety includes an alkyl group of between about four and thirty carbons. Specific examples of suitable hydrophobic moieties include the following alkyl groups n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, n-undecyl, n-dodecyl, n-tetradecyl, n-octadecyl, 2-ethylhexyl, 3-propyl-6-methyl decyl and combinations thereof. Other examples of suitable hydrophobic moieties include haloalkyl groups of at least six carbons (e.g., 10-halodecyl), hydroxyalkyl groups of at least six carbons (e.g., 11-hydroxyundecyl), and aralkyl groups (e.g., benzyl).
- The positively charged region or regions of the fat-binding polymers include but are not limited to, for example, an amine nitrogen capable of possessing a positive charge under conditions present in the gastro-intestinal tract and a quaternary amine-containing moiety. Suitable quaternary amine-containing moieties include alkyl trialkylammonium groups also referred to as ammonioalkyl groups. The term, “ammonioalkyl”, as used herein, refers to an alkyl group which is substituted by a nitrogen bearing three additional substituents. Thus, the nitrogen atom is an ammonium nitrogen atom which bears an alkylene substituent, which links the ammonium nitrogen atom to the polymer, and three additional terminal alkyl substituents having from about one to about twenty-four carbons. A “terminal substituent” of the quaternary amine-containing moiety, as the term is employed herein, is any one of the three substituents on the quaternary amine nitrogen which is not the carbon chain between the polymer backbone and the nitrogen of the quaternary ammonium center. In a specific embodiment, the polymer is an amine polymer and the alkylene group links the ammonium nitrogen atom to the nitrogen atom of the polymer. It is to be understood that multiple moieties can be bound to the same amine and/or different amines of the polymer composition.
- In another embodiment, the quaternary amine-containing moiety can bear at least one terminal hydrophobic alkyl substituent, such as an alkyl group having between about four and twenty-four carbons, thereby providing both a hydrophobic region and a positively charged region in combination.
- An ammonioalkyl group will further include a negatively charged counterion, such as a conjugate base of a pharmaceutically acceptable acid. Examples of suitable counterions include Cl −, PO4 −, Br−, CH3SO3 −, HSO4 −, SO4 2−, HCO3 −, CO3 2−, acetate, lactate, succinate, propionate, butyrate, ascorbate, citrate, maleate, folate, an amino acid derivative, and a nucleotide.
-
- wherein, R 1, R2 and R3 represent an alkyl group, wherein each R1-R3, independently, is a normal or branched, substituted or unsubstituted alkyl group having a carbon atom chain length of between about one to about twenty-four carbon atoms, n is an integer having a value of two or more and Y is a negatively charged counterion. In a particular embodiment, R1, R2 and R3 are all methyl groups and n is an integer between about 2 and about 12 (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12).
- The alkyl group, which provides the alkylene linking group between the polymer, for example, and the amine of the amine-containing monomer or repeat unit, and the ammonium nitrogen of the alkyl trialkylammonium group, is two or more carbon atoms in length. Examples of preferred alkylene linking groups are ethyl, propyl, butyl, pentyl, hexyl, octyl, and decyl groups. Example of suitable quaternary amine-containing moieties include, but are not limited to:
- 3-(trimethylammonio)propyl;
- 4-(trimethylammonio)butyl;
- 6-(trimethylammonio)hexyl;
- 8-(trimethylammonio)octyl;
- 10-(trimethylammonio)decyl;
- 12-(trimethylammonio)dodecyl and combinations thereof A particularly preferred amine-containing moiety is a 6-(trimethylammonio)hexyl group.
- Alternatively, a quaternary amine-containing moiety and a hydrophobic moiety are present in the same substituent, thereby providing both a positively charged and hydrophobic region in combination. For example, the quaternary amine nitrogen or ammonium nitrogen of the quaternary amine-containing moiety is bound to the polymer backbone by an alkylene having two or more carbons. However, at least one of the three terminal substituents (R 1, R2 and R3) of the ammonium nitrogen is a hydrophobic alkyl group having from four to about twenty-four carbons. The remaining terminal substituents are each independently a normal or branched, substituted or unsubstituted alkyl group having from one to about twenty-four carbons or a hydrogen atom. In another embodiment, at least two of the three terminal substituents can be hydrophobic alkyl groups having from four to about twenty-four carbons, the remainder having from one to about twenty-four carbons or a hydrogen atom. In a further embodiment, all three of the terminal substituents can be hydrophobic alkyl groups having from six to about twenty-four carbons.
- A “hydrophobic alkyl group”, as that term is employed herein, includes a substituted or unsubstituted alkyl group having from four to about twenty-four carbons and which is hydrophobic, as earlier defined. The hydrophobic alkyl group can be, for example, a normal or branched, substituted or unsubstituted alkyl group having from six to about twenty-four carbons.
- Particular examples of quaternary amine-containing moieties, which provide both a hydrophobic and quaternary amine-containing substituent, include, but are not limited to:
- 4-(dioctylmethylammonio)butyl;
- 3-(dodecyldimethylammonio)propyl;
- 3-(octyldimethylammonio)propyl;
- 3-(decyldimethylammonio)propyl;
- 5-(dodecyldimethylammonio)pentyl;
- 6-(dimethyldecylammonio)hexyl;
- 6-(decyldimethylammonio)hexyl;
- 3-(tridecylammonio)propyl;
- 3-(docosyldimethylammonio)propyl;
- 6-(docosyldimethylammonio)hexyl;
- 4-(dodecyldimethylammonio)butyl;
- 3-(octadecyldimethylammonio)propyl;
- 3-(hexyldimethylammonio)propyl;
- 3-(methyldioctylammonio)propyl;
- 3-(didecylmethylammonio)propyl;
- 3-(heptyldimethylammonio)propyl;
- 3-(dimethylnonylammonio)propyl;
- 6-(dimethylundecylammonio)hexyl;
- 4-(heptyldimethylammonio)butyl;
- 4-(dioctylmethylammonio)butyl;
- 6-(octyldimethylammonio)hexyl;
- 12-(decyldimethylammonio)dodecyl;
- 3-(dimethylundecylammnio)propyl; and
- 3-(tetradecyldimethylammonio)propyl.
- Other suitable quaternary amine-containing moieties include secondary and tertiary analogs, such as 4-(dioctylmethylammonio) 4-methylbutyl and 4-(dioctylmethylammonio)-4,4-dimethylbutyl.
- The fat-binding polymers of the invention can be formed, for example, by reacting a polymer, which can be linear or crosslinked, with a suitable alkylating agent or by polymerizing an alkylated monomer.
- An “acylating agent”, as that term is employed herein, means a reactant that, when reacted with a monomer or a copolymer characterized by a repeat unit of the invention and having a nucleophilic site capable of reaction with the acylating agent, causes an acyl substituent, in particular a hydrophobic acyl substituent, as described herein, to be covalently bound to one or more of sites on the fat-binding polymer, for example, the amine nitrogen atoms or hydroxyl oxygens of an amine-containing or hydroxyl-containing monomer or polymer, respectively. Further, when multiple substituents are employed, they can be bound to the same and/or different nucleophilic sites of the fat-binding polymer, for example, the same and/or different amine nitrogens of an amine-containing fat-binding polymer or hydroxyl oxygen of a hydroxyl-containing polymer.
- Suitable acylating agents are compounds comprising an acyl group or acyl derivative, for example an anhydride. For example, when the acylating agent is acetic anhydride the nucleophile is modified by addition of an acetyl group. Acylating agents suitable for the addition of a hydrophobic moiety contain an acyl group having at least four carbon atoms, which is bonded to a leaving group such as a halo (e.g., chloro, bromo or iodo). Activated esters are also suitable acylating agents. Examples of suitable acylating agent which provide a hydrophobic moiety include acyl halides having at least four carbon atoms, such as butyryl halide, valeryl halide, hexanoyl halide, heptanoyl halide, octanoyl halide, nonanoyl halide, decanoyl halide, undecanoyl halide, and combinations thereof.
- An “alkylating agent”, as that term is employed herein, means a reactant that, when reacted with a monomer or a copolymer characterized by a repeat unit of the invention and having a nucleophilic site capable of reaction with the alkylating agent, causes a hydrophobic substituent, as described herein, to be covalently bound to one or more of sites on the fat-binding polymer, for example, the amine nitrogen atoms or hydroxyl oxygens of an amine-containing or hydroxyl-containing monomer or polymer, respectively. Further, when multiple substituents are employed, they can be bound to the same and/or different nucleophilic sites of the fat-binding polymer, for example, the same and/or different amine nitrogens of an amine-containing fat-binding polymer or hydroxyl oxygen of a hydroxyl-containing polymer.
- Suitable alkylating agents are compounds comprising an alkyl group or alkyl derivative, having at least four carbon atoms, which is bonded to a leaving group such as a halo (e.g., chloro, bromo or iodo), tosylate, mesylate or epoxy group).
- Examples of suitable alkylating agents which provide a hydrophobic moiety include alkyl halides having at least four carbon atoms, such as n-hexyl halide, n-heptyl halide, n-octyl halide, n-nonyl halide, n-decyl halide, n-undecyl halide, n-dodecyl halide, n-tetradecyl halide, n-octadecyl halide, and combinations thereof. Other examples include: a dihaloalkane that includes an alkyl group of at least four carbons (e.g., a 1,10-dihalodecane); a hydroxyalkyl halide having at least four carbon atoms (e.g., an 11-halo-1-undecanol); an aralkyl halide (e.g., a benzyl halide); an alkyl epoxy ammonium salt having at least six carbons (e.g., glycidylpropyl-trimethylammonium salts) and epoxyalkylamides having at least six carbons (e.g., N-(2,3-epoxypropyl) butyramide or N-(2,3-epoxypropyl) hexanamide). Preferred halogen components of the alkyl halides are bromine and chlorine. Particularly preferred alkylating agents which, when reacted with the polymer composition, will cause formation of an amine polymer reaction product that includes a first substituent, are 1-bromodecane and 1-chlorooctane.
-
- wherein,
- R 1, R2, and R3 represent an alkyl group, wherein each R independently is a normal or branched, substituted or unsubstituted alkyl group having a carbon atom chain length of between about one to about twenty four carbon atoms,
- n is an integer having a value of two or more,
- X is a leaving group as earlier described, and
- Y is a negatively charged counterion.
- When at least one of the three terminal substituents of the quaternary amine alkylating agent is a hydrophobic alkyl group having from four to about twenty-four carbons, the alkylating agent therefore provides both a hydrophobic moiety and a quaternary amine-containing moiety. The alkylene group in this instance is three or more carbon atoms in length.
- Particular examples of quaternary ammonium compounds suitable as alkylating agents include the following:
- (4-bromobutyl)dioctylmethylammonium bromide;
- (3-bromopropyl)dodecyldimethylammonium bromide;
- (3-chloropropyl)dodecyldimethylammonium bromide;
- (3-chloropropyl)decyldimethylammonium bromide;
- (5-tosylpentyl)dodecyldimethylammonium bromide;
- (6-bromohexyl)dimethyldecylammonium bromide;
- (12-bromododecyl)decyldimethylammonium bromide;
- (3-bromopropyl)tridecylammonium bromide;
- (3-bromopropyl)docosyldimethylammonium bromide;
- (6-bromohexyl)docosyldimethylammonium bromide;
- (4-chlorobutyl)dodecyldimethylammonium bromide;
- (3-chloropropyl)octadecyldimethylammonium bromide;
- (3-bromopropyl)octyldimethylammonium bromide;
- (4-iodobutyl)dioctylmethylammonium bromide;
- (2,3-epoxy propyl)decyldimethylammonium bromide; and
- (6-bromohexyl)docosyldimethyammonium bromide.
- Other suitable alkylating agents include secondary and tertiary analogs, such as (3-bromobutyl)dioctylmethylammonium bromide and (3-chloro-3,3-dimethyl propyl)dioctylmethylammonium bromide.
- Examples of suitable alkyl trimethylammonium alkylating agents include alkyl halide trimethylammonium salts, such as:
- (4-halobutyl)trimethylammonium salt;
- (5-halopentyl)trimethylammonium salt;
- (6-halohexyl)trimethylammonium salt;
- (7-haloheptyl)trimethylammonium salt;
- (8-halooctyl)trimethylammonium salt;
- (9-halononyl)trimethylammonium salt;
- (10-halodecyl) trimethylammonium salt;
- (11-haloundecyl)trimethylammonium salt;
- (12-balododecyl)trimethylammonium salt; and combinations thereof. A particularly preferred quaternary amine-containing alkylating agent is (6-bromohexyl)-trimethylammonium bromide.
- In another embodiment, the fat-binding polymer can be have a lipase inhibitor covalently bound to the polymer as described in U.S. Ser. No. 09/005,379 filed on Jan. 9, 1998, and U.S. Ser. No. 09/166,510, entitled “Lipase Inhibiting Polymers” being filed concurrently herewith, the entire contents of both of which are incorporated herein by reference. In a further embodiment, the fat-binding polymer can be administered in combination with a lipase inhibitor which is convalently bound to a polymer as described in U.S. Ser. No. 09/005,379 filed on Jan. 9, 1998, and U.S. Ser. No. 09/166,510 entitled “Lipase Inhibiting Polymers” being filed concurrently herewith, the entire contents of which are incorporated herein by reference.
- As used herein, the terms “therapeutically effective amount” and “therapeutic amount” are synonymous. The terms refer to an amount which is sufficient to treat obesity, reduce the absorption of fat or treat hypertriglyceridemia. The dosage of fat-binding polymer administered to the patient will vary depending among other things on the weight of the patient and the general health of the patient. The dosage can be determined with regard to established medical practice. The amount of fat-binding polymer administered can be in the range of from about 0.01 mg/kg of body weight/day to about 1 g/kg of body weight/day. The amount of lipase inhibitor which can be administered in combination with the fat-binding polymers of the invention can be determined with regard to accepted medical practice.
- As disclosed above, in a preferred embodiment, the fat-binding polymer is administered in combination with a lipase inhibitor, as described herein. The term “in combination” in this context includes both simultaneous or sequential administration (either type of compound first) of the fat-binding polymer and lipase inhibitor. The fat-binding polymer and lipase inhibitor, when used in combination, can be employed together in the same dosage form or in separate dosage forms taken at the same time or within a time period, wherein both the fat-binding polymer and lipase inhibitor are present in a therapeutically effective amount.
- The fat-binding polymers of the invention can be formulated using conventional inert pharmaceutical adjuvant materials into dosage forms which are suitable for oral administration. The oral dosage forms include tablets, capsules, suspension, solutions, and the like. The identity of the inert adjuvant materials which are used in formulating the fat-binding polymers of the invention will be immediately apparent to persons skilled in the art. These adjuvant materials, either inorganic or organic in nature, include, for example, gelatin, albumin, lactose, starch, magnesium stearate, preservatives (stabilizers), melting agents, emulsifying agents, salts, and buffers.
- In patients with hypertriglyceridemia it is to be understood that the patient does not necessarily suffer from hypercholesterolemia.
- Diallylamine (DAA) (2000.3 g) was added slowly over a period of 2 days to concentrated HCl (2035.6 g). The temperature of the reaction was maintained below 10° C. by cooling the flask in an ice-salt-water bath, and by adjusting the addition rate. The room temperature pH of the resulting DAA-HCl solution (68.16% DAA-HCl) was 0.005.
- To a 12-liter, 4-necked, round-bottomed flask equipped with an overhead stirrer and an air condenser was added DAA-HCl (3667.8 g of a 68.16% solution, and deionized water (4665.5 g). The resulting solution had a pH of 0.741. To the flask was added NaOH (66.8 g of a 50% aqueous solution). The resulting solution had a pH of 2.554. Nitrogen gas was bubbled through the solution, via a stainless steel needle, with stirring, and venting on top of the air condenser for 2 hours. The nitrogen line was put on top of the air condenser with positive pressure from a mineral oil bubbler. To the flask was added 125.0 g of freshly made 20% V-50 (Wako Chemicals USA, Inc., Richmond, Va.) in deionized water. This was added via syringe through a septum. The V-50 solution was not degassed with nitrogen. The solution was heated to 60° C. over a period of 1 hour and 8 minutes, with a heating mantle connected to a J-Kem temperature controller. The solution was heated at 60° C. for 18 hours. After the first 18 hour heating period, the reaction solution was allowed to cool down slowly to 49° C., and to the flask was added 125.0 g of freshly made 20% V-50 in deionized water. The solution was heated to 60° C. over a period of about 15 minutes, with a heating mantle connected to a J-Kem temperature controller. The solution was heated at 60° C. for 18 hours. After the second 18 hour heating period, the reaction solution was allowed to cool down slowly to 40° C., and to the flask was added 125.0 g of freshly made 20% V-50 in deionized water. The solution was heated to 60° C. over a period of about 15 minutes, with a heating mantle connected to a J-Kem temperature controller. The solution was heated at 60° C. for 18 hours. After cooling to room temperature, the solution was a dark orange viscous, flowable, clear solution. The flask contents were combined with deionized water (4166.7 g). The resulting solution had a pH of 4.4. SEC analysis: Mw 61494 Daltons; Polydispersity 2.43.
- Poly(allylamine) Hydrochloride (200 g of 50% aqueous solution, 1.07 mol monomer equivalents) was dissolved in a mixture of ethanol (213 mL) and water (125 mL) in a 1-liter, round-bottomed flask equipped with an overhead mechanical stirrer. The pH of the solution was brought to 10.0-10.2 by the addition of NaOH (50% solution). Epichlorohydrin (2.97 g, 32.07 mmol) was then added to the rapidly stirred solution in one portion. This mixture was stirred at room temperature (19-22° C.) until a gel formed (approx. 30 min), then stirring was suspended and the mixture was allowed to sit at room temperature for 20 hours. After the 20 hour reaction time had elapsed, the gel was transferred into a 5-liter bucket with 3 liters of deionized water. The mixture was then stirred with an overhead mechanical stirrer until the gel was well dispersed in solution. The pH was then adjusted to <1 using concentrated HCl. The mixture was then vacuum filtered through Whatman 541 filter paper. The filtered polymer gel was then collected and purified by suspension into 4 liters of deionized water followed by vacuum filtration through Whatman 541 filter paper. The procedure of suspension into deionized water followed by vacuum filtration was repeated several times until the conductivity of the suspended polymer gel was <0.5 mS/cm. After the final vacuum filtration, the polymer gel was transferred into several Pyrex drying trays and placed into a convection oven at 70° C. to dry (24-48 hours). The dried solid was ground to a fine powder using a lab mill with stainless steel blades, and was passed through a sieve (50 mesh) to remove large granules. The ground product was then placed in a vacuum oven at 60° C. and 28 mm Hg for at least 16 hours. Yield=83%.
TABLE 1 Epichlorohydrin Crosslinking Reactions Using a Procedure Similar to Example 3 Example Polyamine mol % Xlink 4 Poly(allylamine) HCl 6 5 Poly(allylamine) HCl 9 6 Poly(allylamine) HCl 10 mol % C 12H 25 3 (prepared according to Example 82) 7 Polyethylenimine 3 8 Polyethylenimine 6 9 Poly(diallylamine) HCl 3 10 Poly(diallylamine) HCl 4.5 11 Poly(diallylamine) HCl 6 12 Poly(diallylmethylamine) HCl 4.5 13 Poly(vinylamine) 4.5 - Poly(allylamine) Hydrochloride (200 g of 50% aqueous solution, 1.07 mol monomer equivalents) was dissolved a mixture of ethanol (213 mL) and water (125 mL) in a 1-liter, round-bottomed flask equipped with an overhead mechanical stirrer. The pH of the solution was brought to 10.0-10.2 by the addition of NaOH (50% solution). Epichlorohydrin (743 mg, 8.03 mmol) was then added to the rapidly stirred solution in one portion at room temperature (19-22° C.). This mixture was stirred at room temperature (19-22° C.) for 20 hours. After the 20 hour reaction time had elapsed, the pH was adjusted to 11.5-12.0 by the addition of a 50% NaOH solution. The reaction mixture was then poured into a 5-liter beaker containing 2 liters of methanol stirred with an overhead mechanical stirrer. A fine precipitate was observed as this mixture was stirred for 30 minutes. The mixture was vacuum filtered through Whatman 541 filter paper, and the clear filtrate was acidified with concentrated HCl (pH<1) producing a thick polymer precipitate and a cloudy solution. The cloudy methanol solution was decanted away from the crude solid product. The precipitate was dissolved in a minimum amount of water (approx. 300 mL) and acidified with concentrated HCl to a pH of <2. The aqueous polymer solution was then poured with overhead mechanical stirring into a 3-liter beaker containing at least 5 volumes (approx. 1.5 liters) of methanol (Isopropanol can be used in place of methanol in this step). The polymeric product precipitated as a white solid. After stirring for 15 minutes, the precipitate was separated from solution by decantation and suspended in 2 liters of isopropyl alcohol. The solid was broken up using a metal spatula and the mixture was stirred for 2 hours. The isopropyl alcohol was then removed by decanting and the product was again suspended in 2 liters of fresh isopropyl alcohol. After 2 hours of stirring, the solvent was decanted away and the solid product was placed in a convection oven at 70° C. to dry (24-48 hours). The dried solid was ground to a fine powder using a lab mill with stainless steel blades, and was passed through a sieve (50 mesh) to remove large granules. The ground product was then placed in a vacuum oven at 60° C. and 28 mmHg for at least 16 hours. Yield=88%.
- Poly(diallylamine) Hydrochloride (3250 g of 20% aqueous solution, 4.86 mol monomer equivalents) was placed in a 20-liter bucket equipped with an overhead mechanical stirrer. The pH of the solution was brought to 10.6 by the addition of NaOH (50% solution). Epichlorohydrin (2.86 mL, 0.037 mol) was then added to the rapidly stirred solution in one portion at room temperature (19-22° C.). This mixture was stirred at room temperature (19-22° C.) for 20 hours. A viscous solution resulted. Methanol (10 liters) was added, and the pH was adjusted to >11.5 using a 50% NaOH solution. This solution was then filtered to remove insoluble crosslinked polymer. The clear filtrate was acidified with concentrated HCl to a pH of <2, and the polymer product was precipitated with the addition of a large volume of ethanol. The solid was collected by decantation and washed with isopropanol. The solid product was then placed in a convection oven at 70° C. to dry (24-48 hours). The dried solid was ground to a fine powder using a lab mill with stainless steel blades, and was passed through a sieve (50 mesh) to remove large granules. The ground product was then placed in a vacuum oven at 60° C. and 28 mmHg for at least 16 hours. Yield=355 g
- Epichlorohydrin (3 mol %) crosslinked poly(allylamine)HCl (100 g of dry solid, 1.05 mol monomer equivalents) was suspended in methanol (1250 mL) in a 3-liter, round-bottomed flask equipped with an overhead mechanical stirrer, a condenser, and a thermocouple probe. Deionized water (750 mL) was slowly added to the suspension with good stirring, and the mixture was stirred until a uniform suspension resulted (approx. 3 hours). The mixture was then heated to 70° C., and the pH of the solution was brought to 10.0-10.2 by the addition of NaOH (50% solution). 1-Bromododecane (26.17 g, 0.105 mol) was then added to the stirred solution in one portion. This mixture was stirred at 70° C. for 20 hours. The solution pH was checked periodically during this time, and was maintained at 10.0-10.2 by the addition of small quantities of 50% NaOH. After the 20 hour reaction time had elapsed, the mixture was cooled to room temperature and the pH was adjusted to <1 using concentrated HCl. The reaction mixture was then poured into a 5-liter beaker containing 3 liters of methanol stirred with an overhead mechanical stirrer. The mixture was stirred until a uniform suspension resulted. The mixture was then vacuum filtered through Whatman 541 filter paper. The filtered polymer gel was collected and suspended in 3 liters of fresh methanol. The methanol suspension was acidified to a pH of <1 with concentrated HCl. The mixture was then vacuum filtered through Whatman 541 filter paper. The filtered polymer gel was collected and suspended in 4-liters of 2M aqueous NaCl. The aqueous suspension was acidified to a pH of <1 with concentrated HCl. The mixture was then vacuum filtered through Whatman 541 filter paper. The filtered polymer gel was then collected and purified by suspension into 4 liters of deionized water followed by vacuum filtration through Whatman 541 filter paper. The procedure of suspension into deionized water followed by vacuum filtration was repeated several times until the conductivity of the suspended polymer gel was <0.5 mS/cm. After the final vacuum filtration, the polymer gel was transferred into several Pyrex drying trays and placed into a convection oven at 70° C. to dry (24-48 hours). The dried solid was ground to a fine powder using a lab mill with stainless steel blades, and was passed through a sieve (50 mesh) to remove large granules. The ground product was then placed in a vacuum oven at 60° C. and 28 mmHg for at least 16 hours. Yield=82%.
TABLE 2 Alkylation Reactions of Xlinked Polyamines Using the Procedure in Example 16 Example Polyamine Alkylating Agent mol % 17 Poly(allylamine)HCl Xlink 3 mol % 1-Bromohexane 5 18 Poly(allylamine)HCl Xlink 3 mol % 1-Bromohexane 10 19 Poly(allylamine)HCl Xlink 3 mol % 1-Bromohexane 25 20 Poly(allylamine)HCl Xlink 3 mol % 1-Bromohexane 50 21 Poly(allylamine)HCl Xlink 3 mol % 1-Bromooctane 5 22 Poly(allylamine)HCl Xlink 3 mol % 1-Bromooctane 10 23 Poly(allylamine)HCl Xlink 3 mol % 1-Bromooctane 25 24 Poly(allylamine)HCl Xlink 3 mol % 1-Bromooctane 50 25 Poly(allylamine)HCl Xlink 3 mol % 1-Bromododecane 5 26 Poly(allylamine)HCl Xlink 3 mol % 1-Bromododecane 25 27 Poly(allylamine)HCl Xlink 3 mol % 1-Bromododecane 50 28 Poly(allylamine)HCl Xlink 3 mol % 1-Bromooctadecane 5 29 Poly(allylamine)HCl Xlink 3 mol % 1-Bromooctadecane 10 30 Poly(allylamine)HCl Xlink 3 mol % 1-Bromooctadecane 25 31 Poly(allylamine)HCl Xlink 3 mol % 1-Bromo-2-ethylhexane 5 32 Poly(allylamine)HCl Xlink 3 mol % 1-Bromo-2-ethylhexane 10 33 Poly(allylamine)HCl Xlink 3 mol % 1-Bromo-2-ethylhexane 25 34 Poly(allylamine)HCl Xlink 3 mol % 1-Bromo-2-ethylhexane 50 35 Poly(allylamine)HCl Xlink 3 mol % (Bromomethyl)cyclohexane 5 36 Poly(allylamine)HCl Xlink 3 mol % (Bromomethyl)cyclohexane 10 37 Poly(allylamine)HCl Xlink 3 mol % (Bromomethyl)cyclohexane 25 38 Poly(allylamine)HCl Xlink 3 mol % (3-Bromopropyl)trimethyl- 5 ammonium Bromide 39 Poly(allylamine)HCl Xlink 3 mol % (3-Bromopropyl)trimethyl- 10 ammonium Bromide 40 Poly(allylamine)HCl Xlink 3 mol % (3-Bromopropyl)trimethyl- 25 ammonium Bromide 41 Poly(allylamine)HCl Xlink 3 mol % (6-Bromohexyl)trimethyl- 10 ammonium Chloride 42 Poly(allylamine)HCl Xlink 3 mol % 1,3-Propane Sultone 5 43 Poly(allylamine)HCl Xlink 3 mol % 1,3-Propane Sultone 10 44 Poly(allylamine)HCl Xlink 3 mol % 1,3-Propane Sultone 25 45 Poly(allylamine)HCl Xlink 3 mol % 1-Bromoacetic Acid 5 46 Poly(allylamine)HCl Xlink 3 mol % 1-Bromoacetic Acid 10 47 Poly(allylamine)HCl Xlink 3 mol % 1-Bromoacetic Acid 25 48 Poly(allylamine)HCl Xlink 3 mol % 2-Bromoethanesulfonic Acid 5 Na salt 49 Poly(allylamine)HCl Xlink 3 mol % 2-Bromoethanesulfonic Acid 10 Na salt 50 Poly(allylamine)HCl Xlink 3 mol % 2-Bromoethanesulfonic Acid 25 Na salt 51 Poly(allylamine)HCl Xlink 3 mol % 2-Bromododecane 10 (6-Bromohexyl) 10 trimethylammonium Chloride 52 Poly(allylamine)HCl Xlink 6 mol % 2-Bromododecane 10 53 Poly(allylamine)HCl Xlink 6 mol % 2-Bromododecane 10 (6-Bromohexyl) 10 trimethylammonium Chloride 54 Poly(allylamine)HCl Xlink 3 mol % (4-chlorobutyl) 10 dodecyldimethylammonium Bromide 55 Poly(allylamine)HCl Xlink 3 mol % (4-chlorobutyl) 40 dodecyldimethylammonium Bromide 56 Poly(ethylenimine) Xlink 3 mol % 1-Bromohexane 5 57 Poly(ethylenimine) Xlink 3 mol % 1-Bromohexane 10 58 Poly(ethylenimine) Xlink 3 mol % 1-Bromohexane 25 59 Poly(ethylenimine) Xlink 3 mol % 1-Bromooctane 5 60 Poly(ethylenimine) Xlink 3 mol % 1-Bromooctane 10 61 Poly(ethylenimine) Xlink 3 mol % 1-Bromooctane 25 62 Poly(ethylenimine) Xlink 3 mol % 1-Bromododecane 5 63 Poly(ethylenimine) Xlink 3 mol % 1-Bromododecane 10 64 Poly(ethylenimine) Xlink 3 mol % 1-Bromododecane 25 65 Poly(diallylamine)HCl Xlink 4.5 1-Bromohexane 5 mol % 66 Poly(diallylamine)HCl Xlink 4.5 1-Bromohexane 25 mol % 67 Poly(diallylamine)HCl Xlink 4.5 1-Bromohexane 50 mol % 68 Poly(diallylamine)HCl Xlink 4.5 1-Bromooctane 5 mol % 69 Poly(diallylamine)HCl Xlink 4.5 1-Bromooctane 30 mol % 70 Poly(diallylamine)HCl Xlink 4.5 1-Bromooctane 40 mol % 71 Poly(diallylamine)HCl Xlink 4.5 1-Bromododecane 5 mol % 72 Poly(diallylamine)HCl Xlink 4.5 1-Bromododecane 11 mol % 73 Poly(diallylamine)HCl Xlink 4.5 1-Bromododecane 25 mol % 74 Poly(diallylamine)HCl Xlink 4.5 (4-chlorobutyl) 10 mol % dodecyldimethylammonium Bromide 75 Poly(diallylamine)HCl Xlink 4.5 (4-chlorobutyl) 20 mol % dodecyldimethylammonium Bromide 76 Poly(diallylamine)HCl Xlink 4.5 (4-chlorobutyl) 30 mol % dodecyldimethylammonium Bromide - Epichlorohydrin (3 mol %) crosslinked poly(allylamine)HCl (57.4 g of dry solid, 0.602 mol monomer equivalents) was suspended in methanol (1 liter) in a 2-liter, round-bottomed flask equipped with an overhead mechanical stirrer, a condenser, and a thermocouple probe. Deionized water (550 mL) was slowly added to the suspension with good stirring, and the mixture was stirred until a uniform suspension resulted (approx. 3 hours). The mixture was then cooled to 15° C. with an ice bath, and the pH of the solution was brought to 9.5 by the addition of NaOH (50% solution). Acetic anhydride (15.41 g, 0.151 mol) was then added to the stirred solution in one portion. This mixture was stirred at 15° C. for 30 minutes. The solution pH was maintained at 9.5 during this time by the addition of small quantities of 50% NaOH. After the 30 minutes it was observed that the pH of the mixture was stable. The crude polymer product was then purified by suspension into 4 liters of deionized water followed by vacuum filtration through Whatman 541 filter paper. The procedure of suspension into deionized water followed by vacuum filtration was repeated several times until the conductivity of the suspended polymer gel was <1 mS/cm. The polymer gel was then suspended in deionized water (2 liters) and the mixture was acidified with concentrated HCl to a pH of <2.5. The mixture was then filtered and transferred into several Pyrex drying trays. The trays were placed into a convection oven at 70° C. to dry (24-48 hours). The dried solid was ground to a fine powder using a lab mill with stainless steel blades, and was passed through a sieve (50 mesh) to remove large granules. The ground product was then placed in a vacuum oven at 60° C. and 28 mmHg for at least 16 hours. Yield=49.9 g
TABLE 3 Acetylation reactions according to the procedure Of Example 77 Example Polyamine mol % Acetylation 78 Poly(allylamine) HCl 50 79 Poly(diallylamine) HCl 25 80 Poly(diallylamine) HCl 50 81 Poly(diallylamine) HCl 100 - Poly(allylamine) Hydrochloride (200 g of 50% aqueous solution, 1.07 mol monomer equivalents) was dissolved a mixture of ethanol (213 mL) and water (125 mL), and was heated to 70° C. in a 1-liter, round-bottomed flask equipped with an overhead mechanical stirrer, a condenser, and a thermocouple probe. The pH of the solution was brought to 10.0-10.2 by the addition of NaOH (50% solution). 1-Bromododecane (26.66 g, 0.107 mol) was then added to the stirred solution in one portion. This mixture was stirred at 70° C. for 20 hours. The solution pH was checked periodically during this time, and was maintained at 10.0-10.2 by the addition of small quantities of 50% NaOH. After the 20 hour reaction time had elapsed, the mixture was cooled to room temperature and the pH was adjusted to 11.5-12.0 by the addition of a 50% NaOH solution. The reaction mixture was then poured into a 5-liter beaker containing 2 liters of methanol stirred with an overhead mechanical stirrer. A fine precipitate was observed as this mixture was stirred for 30 minutes. The mixture was vacuum filtered through Whatman 541 filter paper, and the clear filtrate was acidified with concentrated HCl (pH<1) producing a thick polymer precipitate and a cloudy solution. The cloudy methanol solution was decanted away from the crude solid product. The precipitate was dissolved in a minimum amount of water (approx. 300 mL) and acidified with concentrated HCl to a pH of <2. The aqueous polymer solution was then poured with overhead mechanical stirring into a 3-liter beaker containing at least 5 volumes (approx. 1.5 liters) of methanol (isopropanol can be used in place of methanol in this step). The polymeric product precipitated as a white solid. After stirring for 15 minutes, the precipitate was separated from solution by decantation and suspended in 2 liters of isopropyl alcohol. The solid was broken up using a metal spatula and the mixture was stirred for 2 hours. The isopropyl alcohol was then removed by decanting and the product was again suspended in 2 liters of fresh isopropyl alcohol. After 2 hours of stirring, the solvent was decanted away and the solid product was placed in a convection oven at 70° C. to dry (24-48 hours). The dried solid was ground to a fine powder using a lab mill with stainless steel blades, and was passed through a sieve (50 mesh) to remove large granules. The ground product was then placed in a vacuum oven at 60° C. and 28 mmHg for at least 16 hours. Yield=86%.
- The procedure of Example 82 was used. The 50% aqueous solution of poly(allylamine)HCl was replaced with an equivalent amount of a 50% aqueous solution of the polymer product of Example 14. In place of the 1-bromododecane, 1-bromohexane (17.66 g, 0.107 mol) was used.
- The procedure of Example 82 was used. The 50% aqueous solution of poly(allylamine)HCl was replaced with an equivalent amount of a 50% aqueous solution of the polymer product of Example 14.
- The procedure of Example 82 was used. The 50% aqueous solution of poly(allylamine)HCl was replaced with an equivalent amount of a 50% aqueous solution of the polymer product of Example 14. In place of the 1-bromododecane, 1-bromooctadecane (7.13 g, 0.021 mol) was used.
- The procedure of Example 82 was used. The amount of dodecyl bromide used was 67.3 g, 0.27 mol. The 50% aqueous solution of poly(allylamine)HCl was replaced with an equivalent amount of a 50% aqueous solution of the polymer product of Example 14.
- Poly(allylamine) Hydrochloride 0.75% epichlorohydrin crosslinked from Example 14 (200 g of 50% aqueous solution, 1.07 mol monomer equivalents) was dissolved in a mixture of ethanol (213 mL) and water (125 mL), and was heated to 70° C. in a 1-liter, round-bottomed flask equipped with an overhead mechanical stirrer, a condenser, and a thermocouple probe. The pH of the solution was brought to 10.0-10.2 by the addition of NaOH (50% solution). 1-Bromohexane (44.2 g, 0.27 mol) was then added to the stirred solution in one portion. This mixture was stirred at 70° C. for 20 hours. The solution pH was checked periodically during this time, and was maintained at 10.0-10.2 by the addition of small quantities of 50% NaOH. After the 20 hour reaction time had elapsed, the mixture was cooled to room temperature and the pH was adjusted to 11.5-12.0 by the addition of a 50% NaOH solution. The reaction mixture was then poured into a 5-liter beaker containing 2 liters of methanol stirred with an overhead mechanical stirrer. In this case, no precipitate was formed. The methanol solution was evaporated to dryness giving a stick solid. The solid was dissolved in 800 mL of methanol and 3 liters of hexane was added to precipitate the polymer. After collection by filtration, the polymeric solid was washed with an additional 1 liter of hexane and collected by filtration. The solid product was placed in a convection oven at 70° C. to dry (24-48 hours). The dried solid was ground to a fine powder using a lab mill with stainless steel blades, and was passed through a sieve (50 mesh) to remove large granules. The ground product was then placed in a vacuum oven at 60° C. and 28 mmHg for at least 16 hours. Yield=89.3 g
- Poly(allylamine) Hydrochloride 0.75% epichlorohydrin crosslinked from Example 14 (200 g of 50% aqueous solution, 1.07 mol monomer equivalents) was dissolved in a mixture of ethanol (213 mL) and water (125 mL), and was heated to 70° C. in a 1-liter, round-bottomed flask equipped with an overhead mechanical stirrer, a condenser, and a thermocouple probe. The pH of the solution was brought to 10.0-10.2 by the addition of NaOH (50% solution). 1-Bromohexane (88.4 g, 0.51 mol) was then added to the stirred solution in one portion. This mixture was stirred at 70° C. for 20 hours. The solution pH was checked periodically during this time, and was maintained at 10.0-10.2 by the addition of small quantities of 50% NaOH. After the 20 hour reaction time had elapsed, the mixture was cooled to room temperature giving a white suspension of polymer. The white solid was allowed to settle, and the solution was decanted away. Deionized water (1.5 liters) was added and the slurry was stirred for 15 minutes. The solid was allowed to settle and the solution was removed by decantation. The solid was then dissolved in 800 mL of isopropanol. Concentrated HCl (120 mL) was added but no precipitate was seen. Hexane (3 liters) was added and a white solid precipitated from solution. After collection by filtration, the polymeric solid was washed with an additional 1.5 liters of hexane and collected by filtration. The solid product was placed in a convection oven at 70° C. to dry (24-48 hours). The dried solid was ground to a fine powder using a lab mill with stainless steel blades, and was passed through a sieve (50 mesh) to remove large granules. The ground product was then placed in a vacuum oven at 60° C. and 28 mmHg for at least 16 hours. Yield=117 g
- Poly(allylamine) Hydrochloride 0.75% epichlorohydrin crosslinked from Example 14 (200 g of 50% aqueous solution, 1.07 mol monomer equivalents) was dissolved in a mixture of ethanol (213 mL) and water (125 mL), and was heated to 70° C. in a 1-liter, round-bottomed flask equipped with an overhead mechanical stirrer, a condenser, and a thermocouple probe. The pH of the solution was brought to 10.0-10.2 by the addition of NaOH (50% solution). 1-Bromododecane (13.33 g, 0.054 mol) was then added to the stirred solution in one portion. This mixture was stirred at 70° C. for 20 hours. The solution pH was checked periodically during this time, and was maintained at 10.0-10.2 by the addition of small quantities of 50% NaOH. After the 20 hour reaction time had elapsed, the mixture was cooled to room temperature and the pH was adjusted to 11.5-12.0 by the addition of a 50% NaOH solution. The reaction mixture was then poured into a 5-liter beaker containing 2 liters of methanol stirred with an overhead mechanical stirrer. A fine precipitate was observed as this mixture was stirred for 30 minutes. The mixture was vacuum filtered through Whatman 541 filter paper, and the clear filtrate was acidified with concentrated HCl (pH<1) producing a thick polymer precipitate and a cloudy solution. The cloudy methanol solution was decanted away from the crude solid product. Isopropanol (2.5 liters) was added and the solid was broken into small pieces with a spatula. The solid was collected by decantation and washed a second time with fresh isopropanol. The solid product was placed in a convection oven at 70° C. to dry (24-48 hours). The dried solid was ground to a fine powder using a lab mill with stainless steel blades, and was passed through a sieve (50 mesh) to remove large granules. The ground product was then placed in a vacuum oven at 60° C. and 28 mmHg for at least 16 hours. Yield=81 g
- Poly(allylamine) Hydrochloride 0.75% epichlorohydrin crosslinked from Example 14 (200 g of 50% aqueous solution, 1.07 mol monomer equivalents) was dissolved a mixture of ethanol (213 mL) and water (125 mL), and was heated to 70° C. in a 1-liter, round-bottomed flask equipped with an overhead mechanical stirrer, a condenser, and a thermocouple probe. The pH of the solution was brought to 10.0-10.2 by the addition of NaOH (50% solution). I-Bromooctadecane (17.84 g, 0.054 mol) was then added to the stirred solution in one portion. This mixture was stirred at 70° C. for 20 hours. The solution pH was checked periodically during this time, and was maintained at 10.0-10.2 by the addition of small quantities of 50% NaOH. After the 20 hour reaction time had elapsed, the mixture was cooled to room temperature and poured into a 5-liter beaker containing 2 liters of methanol stirred with an overhead mechanical stirrer. The mixture was acidified with concentrated HCl (pH<1) producing a thick polymer precipitate. The methanol solution was decanted away from the crude solid product, and water (approx. 300 mL) was added to disperse the polymeric product into a slurry. Methanol (900 mL) was added giving a dense precipitate. The solution was decanted away and the polymer was slurried in water a second time and precipitated with methanol. The solid polymer was then washed with 2.5 liters of isopropanol, and then with 1 liter of diethyl ether. The solid product was then placed in a convection oven at 70° C. to dry (24-48 hours). The dried solid was ground to a fine powder using a lab mill with stainless steel blades, and was passed through a sieve (50 mesh) to remove large granules. The ground product was then placed in a vacuum oven at 60° C. and 28 mmHg for at least 16 hours. Yield=111 g
- The procedure of Example 90 was used. The amount of octadecyl bromide used was 35.67 g, 0.107 mol. Yield=124 g
- The procedure of Example 90 was used. The amount of docosyl bromide used was 21.03 g, 0.054 mol. Yield=96 g
- The procedure of Example 90 was used. The amount of docosyl bromide used was 41.68 g, 0.107 mol. Yield=101 g
- Polyethylenimine (200 g of a 50% aqueous solution from Aldrich Chemical Co., 2.32 mol monomer equivalents) was dissolved a mixture of ethanol (213 mL) and water (125 mL), and was heated to 70° C. in a 1-liter, round-bottomed flask equipped with an overhead mechanical stirrer, a condenser, and a thermocouple probe. 1-Bromohexane (95.7 g, 0.58 mol) was then added to the stirred solution in one portion. This mixture was stirred at 70° C. for 20 hours. The solution pH was checked periodically during this time, and was maintained at 10.0-10.2 by the addition of small quantities of 50% NaOH. After the 20 hour reaction time had elapsed, the mixture was cooled to room temperature and poured into a 20-liter bucket containing 3 liters of methanol stirred with an overhead mechanical stirrer. The mixture was acidified with concentrated HCl (pH<2), but no precipitate was formed. Isopropanol (6 liters) was added, giving a small amount of precipitate. Diethyl ether was then added (3 liters) and the crude product precipitated. The solvent was decanted away from the product. The crude product was then redispersed in 750 mL of deionized water. The pH was adjusted to <2 using concentrated HCl. Acetonitrile (5 liters) was then added to precipitate the polymer. The solid was collected by decantation and washed with 2 liters of isopropanol. The solid product was then placed in a convection oven at 70° C. to dry (24-48 hours). The dried solid was ground to a fine powder using a lab mill with stainless steel blades, and was passed through a sieve (50 mesh) to remove large granules. The ground product was then placed in a vacuum oven at 60° C. and 28 mmHg for at least 16 hours. Yield=172 g
- Polyethylenimine (200 g of a 50% aqueous solution from Aldrich Chemical Co., 2.32 mol monomer equivalents) was dissolved in a mixture of ethanol (213 mL) and water (125 mL), and was heated to 70° C. in a 1-liter, round-bottomed flask equipped with an overhead mechanical stirrer, a condenser, and a thermocouple probe. 1-Bromohexane (191.5 g, 1.16 mol) was then added to the stirred solution in one portion. This mixture was stirred at 70° C. for 20 hours. The solution pH was checked periodically during this time, and was maintained at 10.0-10.2 by the addition of small quantities of 50% NaOH. After the 20-hour reaction time had elapsed, the mixture was cooled to room temperature and poured into a 20-liter bucket containing 2 liters of methanol stirred with an overhead mechanical stirrer. The mixture was acidified with concentrated HCl (pH<2), but no precipitate was formed. Diethyl ether was then added (3 liters) and the crude product precipitated. The solvent was decanted away from the product. The crude product was then redispersed in ethanol (3 liters). The pH was adjusted to >11.5 using concentrated NaOH. The free base polymer dissolved, leaving a suspension of salts. The mixture was vacuum filtered through Whatman 541 filter paper, and the clear filtrate was acidified with concentrated HCl (pH<1). Diethyl ether was then added to precipitate the product, which was then collected by decantation. The solid product was then placed in a convection oven at 70° C. to dry (24-48 hours). The dried solid was ground to a fine powder using a lab mill with stainless steel blades, and was passed through a sieve (50 mesh) to remove large granules. The ground product was then placed in a vacuum oven at 60° C. and 28 mmHg for at least 16 hours. Yield=110 g
- Polyethylenimine (200 g of a 50% aqueous solution from Aldrich Chemical Co., 2.32 mol monomer equivalents) was dissolved in a mixture of ethanol (213 mL) and water (125 mL), and was heated to 70° C. in a 1-liter, round-bottomed flask equipped with an overhead mechanical stirrer, a condenser, and a thermocouple probe. 1-Bromododecane (28.9 g, 0.116 mol) was then added to the stirred solution in one portion. This mixture was stirred at 70° C. for 20 hours. The solution pH was checked periodically during this time, and was maintained at 10.0-10.2 by the addition of small quantities of 50% NaOH. After the 20 hour reaction time had elapsed, the mixture was cooled to room temperature and poured into a 20-liter bucket containing 2 liters of methanol stirred with an overhead mechanical stirrer. The mixture was acidified with concentrated HCl (pH<2), resulting in the precipitation of some polymer. Isopropanol was then added (3 liters) and the crude product precipitated. The solvent was decanted away from the product. The crude product was then redispersed in water (750 mL) and methanol (400 mL) and the pH was adjusted to <2 using concentrated HCl. Isopropanol (6 liters) was then added to precipitate the product, which was collected by decantation. The solid product was then placed in a convection oven at 70° C. to dry (24-48 hours). The dried solid was ground to a fine powder using a lab mill with stainless steel blades, and was passed through a sieve (50 mesh) to remove large granules. The ground product was then placed in a vacuum oven at 60° C. and 28 mmHg for at least 16 hours. Yield=146 g
- Polyethylenimine (200 g of a 50% aqueous solution from Aldrich Chemical Co., 2.32 mol monomer equivalents) was dissolved in a mixture of ethanol (213 mL) and water (125 mL), and was heated to 70° C. in a 1-liter, round-bottomed flask equipped with an overhead mechanical stirrer, a condenser, and a thermocouple probe. 1-Bromododecane (57.8 g, 0.232 mol) was then added to the stirred solution in one portion. This mixture was stirred at 70° C. for 20 hours. The solution pH was checked periodically during this time, and was maintained at 10.0-10.2 by the addition of small quantities of 50% NaOH. After the 20 hour reaction time had elapsed, the mixture was cooled to room temperature and poured into a 20-liter bucket containing 2 liters of methanol stirred with an overhead mechanical stirrer. The mixture was acidified with concentrated HCl (pH<2), resulting in the precipitation of some polymer. Isopropanol was then added (3 liters) and the crude product precipitated. The solvent was decanted away from the product. The crude product was then redispersed in water (750 mL) and methanol (400 mL) and the pH was adjusted to <2 using concentrated HCl. Isopropanol (6 liters) was then added to precipitate the product, which was collected by decantation. The solid product was then placed in a convection oven at 70° C. to dry (24-48 hours). The dried solid was ground to a fine powder using a lab mill with stainless steel blades, and was passed through a sieve (50 mesh) to remove large granules. The ground product was then placed in a vacuum oven at 60° C. and 28 mmHg for at least 16 hours. Yield=119 g
- Polyethylenimine (200 g of a 50% aqueous solution from Aldrich Chemical Co., 2.32 mol monomer equivalents) was dissolved in a mixture of ethanol (213 mL) and water (125 mL), and was heated to 70° C. in a 1-liter, round-bottomed flask equipped with an overhead mechanical stirrer, a condenser, and a thermocouple probe. 1-Bromododecane (144.6 g, 0.58 mol) was then added to the stirred solution in one portion. This mixture was stirred at 70° C. for 20 hours. The solution pH was checked periodically during this time, and was maintained at 10.0-10.2 by the addition of small quantities of 50% NaOH. After the 20 hour reaction time had elapsed, the mixture was cooled to room temperature and poured into a 20-liter pail containing 5 liters of ethanol stirred with an overhead mechanical stirrer. The mixture was acidified with concentrated HCl (pH<2), resulting in the precipitation of the crude product. The solvent was decanted, and the crude product was then redissolved in water (750 mL). The pH was adjusted to <2 using concentrated HCl. Isopropanol (6 liters) was then added to precipitate the product, which was collected by decantation. The solid product was then placed in a convection oven at 70° C. to dry (24-48 hours). The dried solid was ground to a fine powder using a lab mill with stainless steel blades, and was passed through a sieve (50 mesh) to remove large granules. The ground product was then placed in a vacuum oven at 60° C. and 28 mmHg for at least 16 hours. Yield=197 g
- Polyethylenimine (200 g of a 50% aqueous solution from Aldrich Chemical Co., 2.32 mol monomer equivalents) was dissolved in a mixture of ethanol (213 mL) and water (125 mL), and was heated to 70° C. in a 1-liter, round-bottomed flask equipped with an overhead mechanical stirrer, a condenser, and a thermocouple probe. 1-bromooctadecane (19.3 g, 0.058 mol) was then added to the stirred solution in one portion. This mixture was stirred at 70° C. for 20 hours. The solution pH was checked periodically during this time, and was maintained at 10.0-10.2 by the addition of small quantities of 50% NaOH. After the 20 hour reaction time had elapsed, the mixture was cooled to room temperature and poured into a 20-liter bucket containing 3.5 liters of methanol stirred with an overhead mechanical stirrer. The mixture was acidified with concentrated HCl (pH<2), resulting in the precipitation of the crude product. The solvent was decanted, and the crude product was then redissolved in water (1100 mL). The pH was adjusted to <2 using concentrated HCl. Isopropanol (6 liters) was then added to precipitate the product, which was collected by decantation. The solid was washed with another 2 liters of clean isopropanol and collected by decantation. The solid product was then placed in a convection oven at 70° C. to dry (24-48 hours). The dried solid was ground to a fine powder using a lab mill with stainless steel blades, and was passed through a sieve (50 mesh) to remove large granules. The ground product was then placed in a vacuum oven at 60° C. and 28 mmHg for at least 16 hours. Yield=169 g
- The procedure of Example 99 was used. The amount of 1-bromooctadecane used 38.7 g, 0.116 mol. Yield=198 g
- Polyethylenimine (200 g of a 50% aqueous solution from Aldrich Chemical Co., 2.32 mol monomer equivalents) was dissolved in a mixture of ethanol (213 mL) and water (125 mL), and was heated to 70° C. in a 1-liter, round-bottomed flask equipped with an overhead mechanical stirrer, a condenser, and a thermocouple probe. 1-Bromodocosane (18.1 g, 0.046 mol) was then added to the stirred solution in one portion. This mixture was stirred at 70° C. for 20 hours. The solution pH was checked periodically during this time, and was maintained at 10.0-10.2 by the addition of small quantities of 50% NaOH. After the 20 hour reaction time had elapsed, the mixture was cooled to room temperature and poured into a 20-liter bucket containing 2.4 liters of ethanol stirred with an overhead mechanical stirrer. The mixture was acidified with concentrated HCl (pH<2), resulting in the precipitation the crude product. The solvent was decanted, and the crude product was then redissolved in water (700 mL). The pH was adjusted to <2 using concentrated HCl. Isopropanol (6 liters) was then added to precipitate the product, which was collected by decantation. The solid was washed with another 2 liters of clean isopropanol and collected by decantation. The solid product was then placed in a convection oven at 70° C. to dry (24-48 hours). The dried solid was ground to a fine powder using a lab mill with stainless steel blades, and was passed through a sieve (50 mesh) to remove large granules. The ground product was then placed in a vacuum oven at 60° C. and 28 mmHg for at least 16 hours. Yield=154 g
- The procedure of Example 101 was used. The amount of 1-bromodocosane used was 45.2 g, 0.116 mol. Yield=160 g
- Poly(diallylamine) Hydrochloride 0.75% epichlorohydrin crosslinked from Example 15 (60 g, 0.45 mol monomer equivalents) was dispersed in ethanol (500 mL) in a 1-liter, round-bottomed flask equipped with an overhead mechanical stirrer, a condenser, and a thermocouple probe. NaOH was added (30 g of a 50% solution), along with deionized water (200 mL) and the mixture was heated to 70° C. The pH of the solution was brought to 10.0-10.2 by the addition of NaOH (50% solution). 1-Bromododecane (5.6 g, 0.023 mol) was then added to the stirred solution in one portion. This mixture was stirred at 70° C. for 20 hours. The solution pH was checked periodically during this time, and was maintained at 10.0-10.2 by the addition of small quantities of 50% NaOH. After the 20 hour reaction time had elapsed, the mixture was cooled to room temperature and poured into a 5-liter beaker containing 3 liters of deionized water stirred with an overhead mechanical stirrer. The crude polymeric product precipitated from solution and was collected by decantation. The crude product was added to a mixture of 300 mL deionized water and 300 mL ethanol. The mixture was acidified with concentrated HCl (pH<1) and stirred for at least 2 hours. Isopropanol (3 liters) was then added to precipitate the product. The solid polymer was then washed with clean isopropanol (2 liters). The solid product was then placed in a convection oven at 70° C. to dry (24-48 hours). The dried solid was ground to a fine powder using a lab mill with stainless steel blades, and was passed through a sieve (50 mesh) to remove large granules. The ground product was then placed in a vacuum oven at 60° C. and 28 mmHg for at least 16 hours. Yield=27 g
- The procedure of Example 104 was used. The amount of 1-bromododecane used was 11.2 g, 0.045 mol. Yield=46 g
- The procedure of Example 104 was used. The amount of 1-bromododecane used was 28.2 g, 0.113 mol. Yield=52 g
- The procedure of Example 104 was used. The amount of 1-bromohexane used was 3.72 g, 0.023 mol.
- The procedure of Example 104 was used. The amount of 1-bromohexane used was 7.43 g, 0.045 mol. Yield=36 g
- The procedure of Example 104 was used. The amount of 1-bromohexane used was 18.65 g, 0.113 mol. Yield=49 g
- The procedure of Example 104 was used. The amount of 1-bromohexane used was 38.0 g, 0.230 mol. Yield=67 g
- The procedure of Example 104 was used. The amount of 1-bromooctadecane used was 3.0 g, 0.009 mol. Yield=23 g
- The procedure of Example 104 was used. The amount of 1-bromooctadecane used was 7.7 g, 0.023 mol. Yield=35 g
- The procedure of Example 104 was used. The amount of 1-bromooctadecane used was 15.0 g, 0.045 mol. Yield=35 g
- To a 1-liter, three-necked flask equipped with condenser and stir bar, were added trimethylaminoethyl acrylchloride quaternary salt (TMAEAC) 50% aqueous solution (150.90 g of 50% solution, 390 mmoles, 78 mole %), acrylamide (7.11 g, 100 mmoles, 20 mole %), octadecyl acrylate (3.25 g, 10 mmoles, 2 mole %) and isopropanol (400 mL). The mixture was purged with nitrogen for 10 min before the addition of a radical initiator, AIBN (330 mg, 2 mmoles). The mixture was heated to 70° C. for 16 hours. At the end of the 16 hour reaction time, the reaction mixture was allowed to cool to room temperature and poured into a beaker containing isopropanol (1 liter). The polymer was precipitated out as a white solid, which was collected and ground to small pieces in a blender using isopropanol as a solvent. The pieces were collected by filtration and the polymer was dried under vacuum at 60° C. for 2 days. The material was ground to a fine powder (82 g), which was used for the in vitro and in vivo studies.
- The following polymers of Table 4 with varying composition of acrylamide, TMAEAC and octadecyl acrylate were prepared using the above procedure.
TABLE 4 Acrylamide TMAEAC Octadecyl Example No. (mole %) (mole %) acrylate (mole %) 114 20 75 5 115 20 70 10 116 35 63 2 117 35 60 5 118 35 55 10 119 50 48 2 120 50 45 5 121 50 40 10 122 0 98 2 123 0 95 5 124 0 90 10 - To a 1-liter, three-necked flask equipped with condenser and stir bar, were added trimethylaminoethyl acrylchloride quaternary salt (TMAEAC) 50% aqueous solution (145.80 g of 50% solution, 375 mmoles, 75 mole %), acrylamide (7.11 g, 100 mmoles, 20 mole %), dodecyl acrylate (6.01 g, 25 mmoles, 5 mole %) and isopropanol (400 mL). The mixture was purged with nitrogen for 10 min before the addition of a radical initiator, AIBN (330 mg, 2 mmoles). The mixture was heated to 70° C. for 16 hours. The reaction mixture was allowed to cool to room temperature and poured into a beaker containing isopropanol (1 liter). The polymer was precipitated out as a white solid, which was collected and ground to small pieces in a blender using isopropanol as a solvent. The pieces were collected by filtration and the polymer was dried under vacuum at 60° C. for 2 days. The material was ground to a fine powder (80 g), which was used for the in vitro and in vivo studies. The polymers of Table 5 were prepared using the above procedure.
TABLE 5 Example Acrylamide TMAEAC Dodecylacrylate No. (mole %) (mole %) (mole %) 126 20 70 10 127 20 55 25 128 35 60 5 129 35 55 10 130 35 40 25 131 50 45 5 132 50 40 10 133 50 25 25 134 0 95 5 135 0 90 10 136 0 75 25 137 0 98 2 138 20 78 2 139 35 63 2 140 50 48 2 - To a 1-liter, three-necked flask equipped with condenser and stir bar, were added trimethylaminoethyl acrylchloride quaternary salt (TMAEAC) 50% aqueous solution (154.76 g of 50% solution, 400 mmoles, 80 mole %), acrylamide (7.11 g, 100 mmoles, 20 mole %), and isopropanol (400 mL). The mixture was purged with nitrogen for 10 min before the addition of a radical initiator, AIBN (330 mg, 2 mmoles). The mixture was heated to 70° C. for 16 hours. At the end of reaction, reaction mixture was allowed to cool to room temperature and poured into a beaker containing isopropanol (1 liter). The polymer was precipitated out as a white solid, which was collected and ground to small pieces in a blender using isopropanol as a solvent. The pieces were collected by filtration and the polymer was dried under vacuum at 60° C. for 2 days. The material was ground to a fine powder (80 g), which was used for the in vitro and in vivo studies.
- The polymers of Table 6 were prepared using the above procedure
TABLE 6 Example No. Acrylamide (mole %) TMAEAC (mole %) 142 0 100 143 10 90 141 20 80 144 35 65 145 50 50 - To a 1-liter, three-necked flask equipped with condenser and stir bar, were added trimethylaminoethyl acrylchloride quaternary salt (TMAEAC) 50% aqueous solution (150.90 g of 50% solution, 390 mmoles, 78 mole %), acrylamide (7.11 g, 100 mmoles, 20 mole %), octadecyl acrylate (3.25 g, 10 mmoles, 2 mole %), methylenebisacrylamide (3.08 g, 20 mmoles, 4 mole %) and ethanol (300 mL) were added. The mixture was purged with nitrogen for 10 min before the addition of a radical initiator, AIBN (330 mg, 2 mmoles). The mixture was heated to 70° C. for 16 hours. At the end of reaction, reaction mixture was allowed to cool to room temperature and poured into a beaker containing isopropanol (1 liter). The polymer was precipitated out as a white solid, which was collected and ground to small pieces in a blender using isopropanol as a solvent. The pieces were collected by filtration and the polymer was dried under vacuum at 60° C. for 2 days. The material was ground to a fine powder (84 g), which was used for the in vitro and in vivo studies.
- The compounds of Table 7 were prepared using the above procedure.
TABLE 7 Octadecyl Example Acrylamide TMAEAC acrylate Methylenebisacryl- No. (mole %) (mole %) (mole %) amide (mole %) 147 20 75 5 4 148 20 70 10 4 149 35 63 2 4 150 35 60 5 4 151 35 55 10 4 152 50 48 2 4 153 50 45 5 4 154 50 40 10 4 155 0 98 2 4 156 0 95 5 4 157 0 90 10 4 - To a 1-liter, three-necked flask equipped with condenser and stir bar, were added trimethylaminoethyl acrylchloride quaternary salt (TMAEAC) 50% aqueous solution (145.80 g of 50% solution, 375 mmoles, 75 mole %), acrylamide (7.11 g, 100 mmoles, 20 mole %), dodecylacrylate (6.01 g, 25 mmoles, 5 mole %), methylenebisacrylamide (3.08 g, 20 mmoles, 4 mole %) and ethanol (300 mL). The mixture was purged with nitrogen for 10 min before the addition of a radical initiator, AIBN (330 mg, 2 mmoles). The mixture was heated to 70° C. for 16 hours. The reaction mixture was allowed to cool to room temperature and poured into a beaker containing isopropanol (1 liter). The polymer was precipitated out as a white solid, which was collected and ground to small pieces in a blender using isopropanol as a solvent. The pieces were collected by filtration and the polymer was dried under vacuum at 60° C. for 2 days. The material was ground to a fine powder (80 g), which was used for the in vitro and in vivo studies. The following cross-linked polymers were prepared.
- The polymers of Table 8 were prepared using the above procedure.
TABLE 8 Dodecyl- Example Acrylamide TMAEAC acrylate Methylenebisacryl- No. (mole %) (mole %) (mole %) amide (mole %) 159 20 70 10 4 160 20 55 25 4 161 35 60 5 4 162 35 55 10 4 163 35 40 25 4 164 50 45 5 4 165 50 40 10 4 166 50 25 25 4 167 0 95 5 4 168 0 90 10 4 169 0 75 25 4 - To a 1 liter, three necked, round-bottomed flask equipped with condenser, stir bar, heating mantle (with J-Kem temperature controller) and nitrogen bubbler was added: trimethylammonioethyl methacrylate chloride (TMAEMC) ˜75% aqueous 87.19 g (420.39 mmol), octadecyl methacrylate (3.65 g, 10.80 mmol), methacrylamide (9.16 g, 107.76 mmol), and ethanol (300 mL). The total amount of monomer solids should be 100 g. Nitrogen was allowed to bubble through the room temperature monomer mixture for at least 20 minutes before adding 0.275 g AIBN [2,2′-azobis(2-methyl-propionitrile)]. At this point the nitrogen was set to blanket the mixture and the heat was turned on to 70° C. The reaction was allowed to heat for 22 hours at 70° C. While the polymer was still warm it was poured from the flask into a Nalgene bucket and allowed to stand for at least three hours in each of four 1-liter washings of isopropanol. Once the polymer became slightly rigid/rubbery it was broken up into small chunks using a blender (with isopropanol as the liquid). The granular product was filtered and washed with more isopropanol and placed in a crystallizing dish in a 70° C. convection oven for two days. After this time, the product was removed and ground to a fine powder using a grinder and placed back in the oven for two more days. GPC analysis of octadecyl methacrylate containing polymers shows MW ranges form 100K-150K with polydispersities ranging from 2.5-5. The following table gives general mole percent compositions of polymers prepared in this fashion. The polymers of Table 9 were prepared using the above procedure.
TABLE 9 Octadecyl Example Methacrylamide TMAEMC Methacrylate No. (mole %) (mole %) (mole %) 171 0 98 2 172 0 95 5 173 0 90 10 174 0 85 15 175 0 80 20 170 20 78 2 176 20 75 5 177 20 70 10 178 35 63 2 179 35 60 5 180 35 55 10 181 50 48 2 182 50 45 5 183 50 40 10 - To a 1-liter, three-necked, round-bottomed flask equipped with condenser, stir bar, heating mantle (with J-Kem temperature controller) and nitrogen bubbler was added: trimethylammonioethyl methacrylate chloride (TMAEMC) ˜75% aqueous (83.97 g, 404.86 mmol), dodecyl methacrylate (6.85 g, 26.96 mmol), methacrylamide (9.18 g, 108.0 mmol), and ethanol (300 mL). The total amount of monomer solids should be 100 g. Nitrogen was allowed to bubble through the room temperature monomer mixture for at least 20 minutes before adding 0.275 g AIBN [2,2′-azobis(2-methyl-propionitrile)]. At this point, the nitrogen was set to blanket the mixture and the heat was turned on to 70° C. The reaction was allowed to heat for 22 hours at 70° C. While the polymer was still warm it was poured from the flask into a Nalgene bucket and allowed to stand for at least three hours in each of four 1-liter washings of isopropanol. Once the polymer became slightly rigid/rubbery it was broken up into small chunks using a blender (with isopropanol as the liquid). The granular product was filtered and washed with more isopropanol and placed in a crystallizing dish in a 70° C. convection oven for two days. After this time, the product was removed and ground to a fine powder using a grinder and placed back in the oven for two more days. GPC analysis of dodecyl methacrylate containing polymers shows MW ranges form 170-190K with polydispersities ranging from 2.3-2.8. Table 10 gives general mole percent compositions of polymers prepared in this fashion.
- The polymers of Table 10 were prepared using the above procedure.
TABLE 10 Example Methacrylamide TMAEMC Dodecyl metrhacrylate No. (mole %) (mole %) (mole %) 185 0 95 5 186 0 90 10 187 0 75 25 184 20 75 5 188 20 70 10 189 20 55 25 190 35 60 5 191 35 55 10 192 35 40 25 193 50 45 5 194 50 40 10 195 50 25 25 - To a 1-liter, three-necked, round-bottomed flask equipped with condenser, stir bar, heating mantle (with J-Kem temperature controller) and nitrogen bubbler was added: trimethylammonioethyl methacrylate chloride (TMAEMC) ˜75% aqueous, (90.71 g, 437.36 mmol), methacrylamide (9.29 g, 109.29 mmol), and ethanol (300 mL). The total amount of monomer solids should be 100 g. Nitrogen was allowed to bubble through the room temperature monomer mixture for at least 20 minutes before adding 0.275 g AIBN [2,2′-azobis(2-methyl-propionitrile)]. At this point, the nitrogen was set to blanket the mixture and the heat was turned on to 70° C. The reaction was allowed to heat for 22 hours at 70° C. While the polymer was still warm it was poured from the flask into a Nalgene bucket and allowed to stand for at least three hours in each of four 1-liter washings of isopropanol. Once the polymer became slightly rigid/rubbery it was broken up into small chunks using a blender (with isopropanol as the liquid). The granular product was filtered and washed with more isopropanol and placed in a crystallizing dish in a 70° C. convection oven for two days. After this time the product was removed and ground to a fine powder using a grinder and placed back in the oven for two more days. Table 11 gives general mole percent compositions of polymers prepared in this fashion.
- The polymers of Table 11 were prepared using the above procedure.
TABLE 11 Example No. Methacrylamide (mole %) TMAEMC (mole %) 197 0 100 196 20 80 198 35 65 199 50 50 - To a 1-liter, three-necked, two-part reaction flask equipped with condenser, mechanical stirrer, water bath, and nitrogen bubbler was added trimethylammonioethyl methacrylate chloride (TMAEMC), ˜75% aqueous (87.19 g, 420.39 mmol) octadecyl methacrylate (3.65 g, 10.80 mmol), methacrylamide (9.16 g, 107.76 mmol), and ethanol (400 mL). The total amount of monomer solids should be 100 g. To this was added an additional 2 mole percent (of total monomers) N,N′-methylenebismethacrylamide (1.96 g, 10.76 mmol). Nitrogen was allowed to bubble through the room temperature monomer mixture for at least 20 minutes before adding 0.275 g AIBN [2,2′-azobis(2-methyl-propionitrile)]. At this point, the nitrogen was set to blanket the mixture and the heat was turned on to 70° C. Once the polymer began to gel the stirring was turned off; total heating time at 70° C. was approximately 5 hours. The polymer was then allowed cool down to room temperature and stand overnight. The gelled product was scooped out of the flask and swollen to a clear gel in a 500 mL isopropanol/1000 mL water mixture. The gel was washed 6×with 1000 mL isopropanol filtering over a 50-mesh sieve. Once the polymer became slightly rigid/rubbery it was broken up into small chunks using a blender (with isopropanol as the liquid). The product was filtered over a sieve, wrung out, and placed in a drying dish in a 70° C. convection oven for two days. After this time, the product was removed and ground to a fine powder using a grinder and placed back in the oven for two more days in a glass crystallizing dish. Table 12 gives general mole percent compositions of polymers prepared in this fashion.
- The polymers of Table 12 were prepared using the above procedure.
TABLE 12 Methacryl- Octadecyl Methylenebismeth- Example amide TMAEMC Methacrylate acrylamide No. (mole %) (mole %) (mole %) (mole %) 201 0 98 2 2 202 0 95 5 2 203 0 90 10 2 204 0 85 15 2 205 0 80 20 2 200 20 78 2 2 206 20 75 5 2 207 20 70 10 2 208 35 63 2 2 209 35 60 5 2 210 35 55 10 2 211 50 48 2 2 212 50 45 5 2 213 50 40 10 2 - To a 11-liter, three-necked, two-part reaction flask equipped with condenser, mechanical stirrer, water bath, and nitrogen bubbler was added: trimethylammonioethyl methacrylate chloride (TMAEMC), ˜75% aqueous solution (83.97 g, 404.86 mmol), dodecyl methacrylate (6.85 g, 26.96 mmol), methacrylamide (9.18 g, 108.0 mmol) and ethanol (400 mL). The total amount of monomer solids should be 100 g. To this was added an additional 2 mole percent (of total monomers) N,N′-methylenebismethacrylamide (1.96 g, 10.79 mmol). Nitrogen was allowed to bubble through the room temperature monomer mixture for at least 20 minutes before adding 0.275 g AIBN [2,2′-azobis(2-methyl-propionitrile)]. At this point, the nitrogen was set to blanket the mixture and the heat was turned on to 70° C. Once the polymer began to gel the stirring was turned off; total heating time at 70° C. was approximately 5 hours. The polymer was then allowed cool down to room temperature and stand overnight. The gelled product was scooped out of the flask and swollen to a clear gel in a 500 mL isopropanol/1000 mL water mixture. The gel was washed 6× with 1000 mL of isopropanol filtering over a 50-mesh sieve. Once the polymer became slightly rigid/rubbery it was broken up into small chunks using a blender (with isopropanol as the liquid). The product was filtered over a sieve, wrung out, and placed in a drying dish in a 70° C. convection oven for two days. After this time, the product was removed and ground to a fine powder using a grinder and placed back in the oven for two more days in a glass crystallizing dish. Table 13 gives general mole percent compositions of polymers prepared in this fashion.
TABLE 3 Methacryl- Dodecyl Methylenebismeth- Example amide TMAEC methacrylate acrylamide No. (mole %) (mole %) (mole %) (mole %) 215 0 95 5 2 216 0 90 10 2 217 0 75 25 2 214 20 75 5 2 218 20 70 10 2 219 20 55 25 2 220 35 60 5 2 221 35 55 10 2 222 35 40 25 2 223 50 45 5 2 224 50 40 10 2 225 50 25 25 2 - To a 1-liter, three-necked, two-part reaction flask equipped with condenser, mechanical stirrer, water bath, and nitrogen bubbler was added: trimethylammonioethyl methacrylate chloride (TMAEMC) ˜75% aqueous solution (90.71 g, 437.36 mmol), methacrylamide 9.29 g (109.29 mmol), and ethanol (400 mL). The total amount of monomer solids should be 100 g. To this was added an additional 2 mole percent (of total monomers) N,N′-methylenebismethacrylamide (1.989 g, 10.93 mmol). Nitrogen was allowed to bubble through the room temperature monomer mixture for at least 20 minutes before adding 0.275 g AIBN [2,2′-azobis(2-methyl-propionitrile)]. At this point, the nitrogen was set to blanket the mixture and the heat was turned on to 70° C. Once the polymer began to gel the stirring is turned off; total heating time at 70° C. was approximately 5 hours. The polymer was then allowed cool down to room temperature and stand overnight. The gelled product was scooped out of the flask and swollen to a clear gel in a 500 mL isopropanol/1000 mL of water mixture. The gel was washed 6×with 1000 mL isopropanol filtering over a 50-mesh sieve. Once the polymer became slightly rigid/rubbery it was broken up into small chunks using a blender (with isopropanol as the liquid). The spongy product is filtered over a sieve, pressed dry, and placed in a drying dish in a 70° C. convection oven for two days. After this time the product was removed and ground to a fine powder using a grinder and placed back in the oven for two more days in a glass crystallizing dish. Table 14 gives general mole percent compositions of polymers prepared in this fashion.
TABLE 14 Example Methacrylamide TMAEMC Methylenebismeth- No. (mole %) (mole %) Acrylamide (mole %) 227 0 100 2 226 20 80 2 228 35 65 2 229 50 50 2 - Method for Determining Binding of Emulsion Particles by Lipid-Binding Polymers Using an Olive Oil Emulsion with Physiological Emulsifiers
- Preparation of Olive Oil Emulsion for Lipid-Binding Assay
- Emulsifier Solution
- Egg yolk lecithin 2.54 mmol (2.00 g) and cholesterol 1.25 mmol (0.483 g) were dissolved in 100 mL of chloroform in a 1-liter, round-bottomed flask and the solvent was removed rapidly using a rotary evaporator. A coating of lecithin and cholesterol resulted, adhering to the walls of the flask. This film was held under vacuum for 12 hours. The sodium salts of the following bile acids were then added to the flask: glycocholic 1.217 g (2.496 mmol), taurocholic 0.895 g (1.664 mmol), glycodeoxycholic 1.766 g (3.744 mmol), taurodeoxycholic 1.302 g (2.496 mmol). An aqueous buffer consisting of 0.1M 2-[N-morpholino]ethanesulfonic acid (MES) and 0.1M sodium chloride was prepared and the pH was adjusted with 50% NaOH to pH=6.5.1 liter of this aqueous buffer was added to the flask containing the coating of lecithin and cholesterol, and this mixture was stirred for 3-4 hours. During this time, the coating of lecithin and cholesterol was dispersed in solution. A cloudy solution resulted.
- Emulsion
- In a 400 mL, thick-walled beaker, were mixed highly refined acid free olive oil 31.49 g, and oleic acid 3.51 g. The emulsifier solution described above was then added to bring the total weight of the mixture to 350 g. A 1-inch drying coated stir bar was added, and the mixture was stirred magnetically for 2-5 minutes. The mixture was then irradiated with 2 bursts of ultrasound (45 sec. each, with 2 minutes of magnetic stirring between bursts) using a Branson Sonifier 450 operated at maximum power with a ¾″ solid horn. The pH of the resulting emulsion was adjusted to 6.5 (at 20° C.). The emulsion prepared in this way was used immediately in the fat binding test, but could be kept in a refrigerator (4° C.) for a week.
- When the physiological emulsion described above was mixed with test polymers, it was observed that a solid polymer/lipid complex would form in some cases. A test was devised to measure the quantity of lipid absorbed by the test polymers from the physiological emulsion.
- Lipid Binding Test
- The test polymer (25 mg) was weighed into a tared 20 mL centrifuge filter cup with a 10 micron polypropylene mesh filter (Whatman VECTASPIN20™ centrifuge filter). The bottom of the filter cup was then sealed with tape to prevent solution from leaking out during the test. Using an analytical pipette, an aqueous buffer solution (3 mL) containing NaCl (0.1M), and MES (0.1M) at pH=6.5 was added to the filter cup. The filter cup was inserted into its companion centrifuge tube and sealed with a cap. This assembly was agitated in an orbital shaker for at least 1 hour in order to dissolve or disperse the test polymer. The olive oil emulsion described above (15 mL) was then added to the filter cup using an analytical pipette. The cap was replaced, and the centrifuge tube shaken (250 rpm) on an orbital mixer for a period of one hour. The centrifuge filter device was then disassembled so that the tape could be removed from the bottom of the centrifuge filter cup. It was immediately reassembled and spun in a centrifuge at an RCF of 500 G, and at 25° C. for 30 minutes. The centrifuge filter device was removed from the centrifuge and disassembled. The filter cup was weighed to obtain the weight gain of the wet polymer/lipid complex. This material was the removed from the filter cup with a spatula, and placed into a tared glass vial. The vial was weighed again to obtain the weight of the polymer/lipid sample. The vial was then placed into a centrifugal evaporator, and dried at 60° C. under vacuum until a pressure of 0.15 Torr or less was achieved (8-18 hrs). The vial was removed and weighed to obtain the dry weight of the polymer/lipid complex sample. The amount of lipid absorbed by the original 25 mg polymer sample in the filter cup was then calculated. This gravimetric result was used as a measure for lipid binding by the polymer, and is listed in the accompanying table as lipid weight absorbed (g) per gram of polymer.
TABLE 15 Lipid weight (g) absorbed EXAMPLE No. by 1 gram of polymer Chitosan 2.2 10 5.5 13 6.8 14 20 15 44.9 16 3.4 52 3.3 54 4.6 55 3.8 66 5.9 67 5.9 69 4.5 70 4.1 72 5.8 75 4.5 76 3.9 78 3 79 3.6 80 12.6 81 3.1 83 10 84 2.7 85 11.3 86 2.1 87 6.5 88 3.1 89 6.9 90 4.5 91 6.2 92 10.9 94 2.8 96 4.7 97 4.5 98 1.7 99 5.7 100 3.3 101 11 102 13.4 103 4.3 104 16 105 2.1 107 7.7 108 6.6 109 5.1 110 6.1 111 4.8 112 3.8 113 60 114 58 115 58 116 59 117 59 118 60 119 54 120 59 121 60 122 56 123 54 124 50 125 59 126 52 127 56 128 66 129 62 130 60 131 59 132 58 133 59 134 49 135 49 136 43 137 57 138 64 140 63 141 66 166 48 167 59 168 61 169 39 172 61 173 33 174 39 175 65 176 15 177 37 178 21 179 24 180 57 181 68 182 60 183 51 184 65 185 7 186 67 187 27 188 2 189 43 190 10 191 2 192 68 193 67 194 61 195 64 196 16 197 8 198 13 199 5 202 9 203 6 204 15 205 7 206 3 207 22 208 4 209 3 - In vivo Testing of Fat-Binding Polymers
- The non-crosslinked and crosslinked fat-binding polymers of Examples 5, 6, 10, 72, 173 and Chitosan were evaluated for their ability to increase the excretion of fat in the feces, relative to the control group, in normal rats over a six-day period. Male Sprague-Dawley rats (five to six weeks of age) were individually housed and fed ad libitum a powdered “high-fat diet,” consisting of standard rodent chow supplemented with 15% lard by weight. After feeding the animals this diet for five days, the animals were weighed and sorted into the treatment or control groups (4-6 animals per group, each group having equal mean body weights). Animals were treated for six days with the test compounds, which were added to the “high-fat diet” at concentrations (w/w) of 0.0% (control), 2.0 or 5.0 percent of the diet. In one study chitosan was evaluated for its effect on fecal fat excretion.
- Rat fecal samples were collected on the final three days of the six days of drug treatment. The samples were freeze dried and ground to a fine powder. One half gram of sample was weighed and transferred to extraction cells. Samples were extracted in an accelerated solvent extractor (ASE 200 Accelerated Solvent Extractor, Dyonex Corporation, Sunnyvale, Calif.) with 95% ethanol, 5% water and 100 mM KOH. The sample was extracted in 17 minutes at 150° C. and 1500 psi. An aliquot of extract was transferred to a test tube containing a molar excess of HCl. The sample was then evaporated and reconstituted in a detergent solution consisting of 2% Triton X-1200, 1% polyoxyethylene lauryl ether and 0.9% NaCl. Fatty acids were then quantitated enzymatically with a colorimetric kit (NEFAC, Wako Chemical GmbH, Neuss, Germany).
- Table 16 contains values for fecal fat excretion as a percentage of ingested fat.
TABLE 16 IN VIVO EFFICACY OF FAT-BINDING POLYMERS FECAL FAT Dose EXCRETION % (w/w percent OF INGESTED Example Identification of diet) FAT Example 6-PAA 3% XL, 5 40 10% C12 Example 6-PAA 3% XL, 10% C12 2 12 Example 5-PAA 9.4% XL 2 22 Example 10-PDA 4.5% XL 2 30 Example 72-PDA 4.5% XL, 11% C12 2 29 Example 173-TMAEMC (90 mol %) + 2 20 octadecyl methacrylate(10 mol %) Chitosan 2 8 - Fecal Fat/Consumed Fat was calculated as follows: Fatty acid concentration from the enzymatic assay was expressed as mmol/mL. The mmol/mL of fatty acid was then multiplied by the number of mL of extract generated from 500 mg of sample to give the total mmol of fatty acid. The value for the total mmol of fatty acid was converted to total mg of fatty acid using the average molecular weight of medium to long chain fatty acid (270 D). The value was corrected for any dilutions made during sample workup. When results are expressed as mg/gm of feces, the total mg of fatty acids is multiplied by 2. When results were expressed as total mg of fatty acid excreted in 24 hours, the mg/gm of feces value was multiplied by fecal weight in grams excreted in 24 hours. When the results were expressed as excreted fat as a % of that consumed in 24 hours, the total weight of fat excreted in 24 hours was divided by the weight of fatty acids consumed over 24 hours and multiplied by 100.
- While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims. Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described specifically herein. Such equivalents are intended to be encompassed in the scope of the claims.
Claims (7)
1. A method for treating obesity in a mammal, comprising the step of orally administering to the mammal an effective amount of one or more fat-binding polymers in combination with one or more lipase inhibitors.
2 The method of claim 1 wherein the lipase inhibitor is selected from lipstatin, tetrahydrolipstatin or a combination thereof.
4. The method of claim 3 herein the hydrophobic region comprises a substituted or unsubstituted, normal, branched or cyclic alkyl group having at least about four carbons.
5. The method of claim 3 wherein the hydrophobic region comprises an alkyl group of between about four and thirty carbons.
6 The method of claim 3 wherein the hydrophobic region comprises an alkyl group of about 6 carbons.
7. A method for reducing the absorption of dietary fat in a mammal, comprising the step of orally administering to the mammal a therapeutic amount of one or more fat-binding polymers in combination with one or more lipase inhibitors.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/307,151 US20030175236A1 (en) | 1998-01-09 | 2002-11-27 | Fat-binding polymers |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US496398A | 1998-01-09 | 1998-01-09 | |
| US09/166,453 US6264937B1 (en) | 1998-01-09 | 1998-10-05 | Fat-binding polymers |
| US72130900A | 2000-11-22 | 2000-11-22 | |
| US10/307,151 US20030175236A1 (en) | 1998-01-09 | 2002-11-27 | Fat-binding polymers |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US72130900A Continuation | 1998-01-09 | 2000-11-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20030175236A1 true US20030175236A1 (en) | 2003-09-18 |
Family
ID=21713424
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/166,453 Expired - Lifetime US6264937B1 (en) | 1998-01-09 | 1998-10-05 | Fat-binding polymers |
| US10/307,151 Abandoned US20030175236A1 (en) | 1998-01-09 | 2002-11-27 | Fat-binding polymers |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/166,453 Expired - Lifetime US6264937B1 (en) | 1998-01-09 | 1998-10-05 | Fat-binding polymers |
Country Status (2)
| Country | Link |
|---|---|
| US (2) | US6264937B1 (en) |
| CN (1) | CN1698647A (en) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6733780B1 (en) * | 1999-10-19 | 2004-05-11 | Genzyme Corporation | Direct compression polymer tablet core |
| US20020054903A1 (en) * | 1999-10-19 | 2002-05-09 | Joseph Tyler | Direct compression polymer tablet core |
| WO2002085382A1 (en) * | 2001-04-18 | 2002-10-31 | Genzyme Corporation | Methods of treating syndrome x with aliphatic polyamines |
| US7041280B2 (en) * | 2001-06-29 | 2006-05-09 | Genzyme Corporation | Aryl boronate functionalized polymers for treating obesity |
| US7049345B2 (en) * | 2001-06-29 | 2006-05-23 | Genzyme Corporation | Fat-binding polymers |
| US6858592B2 (en) * | 2001-06-29 | 2005-02-22 | Genzyme Corporation | Aryl boronic acids for treating obesity |
| CA2546696A1 (en) * | 2002-11-19 | 2004-06-03 | Genzyme Corporation | Polymeric boronic acid derivatives as lipase inhibitors |
| US20100055215A1 (en) * | 2003-06-23 | 2010-03-04 | Calagui Juanito B | Process to lose weight, drain unwanted body fats and other toxins |
| US20050244367A1 (en) * | 2004-05-03 | 2005-11-03 | Ilypsa, Inc. | Phospholipase inhibitors localized in the gastrointestinal lumen |
| US7985418B2 (en) * | 2004-11-01 | 2011-07-26 | Genzyme Corporation | Aliphatic amine polymer salts for tableting |
| US20060177415A1 (en) * | 2004-11-01 | 2006-08-10 | Burke Steven K | Once a day formulation for phosphate binders |
| WO2007027566A2 (en) * | 2005-09-02 | 2007-03-08 | Genzyme Corporation | Method for removing phosphate and polymer used therefore |
| AR056499A1 (en) * | 2005-09-06 | 2007-10-10 | Serapis Farmaceuticals Ltd | COMPOUNDS |
| HUE026628T2 (en) | 2005-09-15 | 2016-06-28 | Genzyme Corp | Sachet formulation for amine polymers |
| EP2016114A2 (en) * | 2006-05-05 | 2009-01-21 | Genzyme Corporation | Amine condensation polymers as phosphate sequestrants |
| CA2658338A1 (en) * | 2006-07-18 | 2008-01-24 | Genzyme Corporation | Amine dendrimers |
| WO2008042222A2 (en) | 2006-09-29 | 2008-04-10 | Genzyme Corporation | Amide dendrimer compositions |
| WO2008076242A1 (en) | 2006-12-14 | 2008-06-26 | Genzyme Corporation | Amido-amine polymer compositions |
| WO2008103368A1 (en) * | 2007-02-23 | 2008-08-28 | Genzyme Corporation | Amine polymer compositions |
| EP2131820A1 (en) * | 2007-03-08 | 2009-12-16 | Genzyme Corporation | Sulfone polymer compositions |
| US20100166696A1 (en) * | 2007-04-27 | 2010-07-01 | Dhal Pradeep K | Amido-amine dendrimer compositions |
| WO2009078958A1 (en) * | 2007-12-14 | 2009-06-25 | Genzyme Corporation | Coated pharmaceutical compositions |
| WO2009154747A1 (en) * | 2008-06-20 | 2009-12-23 | Genzyme Corporation | Pharmaceutical compositions |
| US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
Citations (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3780171A (en) * | 1969-12-27 | 1973-12-18 | Merck Patent Gmbh | Ingestible polymeric compositions |
| US3923972A (en) * | 1971-10-12 | 1975-12-02 | Monsanto Co | Method of lowering blood cholesterol level |
| US4160826A (en) * | 1975-12-12 | 1979-07-10 | Laboratory Biochimici Fargal-Pharmasint S.P.A. | Inhibitor preparation for the absorption of lipids, based on diethylaminoethyldextran |
| US4211765A (en) * | 1971-10-12 | 1980-07-08 | Monsanto Company | Method for controlling obesity |
| US4218443A (en) * | 1979-01-15 | 1980-08-19 | Hoffmann-La Roche Inc. | Polyether ionophores as antiobesity and hypotriglyceridemic agents |
| US4265879A (en) * | 1977-09-13 | 1981-05-05 | Monsanto Company | Method for controlling blood triglycerides |
| US4302450A (en) * | 1979-01-15 | 1981-11-24 | Hoffmann-La Roche Inc. | Polyether ionophores as antiobesity and hypotriglyceridemic agents |
| US4432968A (en) * | 1980-10-20 | 1984-02-21 | The Dow Chemical Company | Weight control with fat imbibing polymers |
| US4598089A (en) * | 1983-06-22 | 1986-07-01 | Hoffmann-La Roche Inc. | Leucine derivatives |
| US4759923A (en) * | 1987-06-25 | 1988-07-26 | Hercules Incorporated | Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives |
| US4959179A (en) * | 1989-01-30 | 1990-09-25 | Lever Brothers Company | Stabilized enzymes liquid detergent composition containing lipase and protease |
| US5063210A (en) * | 1989-04-20 | 1991-11-05 | Lange Iii Louis G | Use of sulfated polysaccharides to decrease cholesterol and fatty acid absorption |
| US5089163A (en) * | 1989-01-30 | 1992-02-18 | Lever Brothers Company, Division Of Conopco, Inc. | Enzymatic liquid detergent composition |
| US5137716A (en) * | 1990-11-15 | 1992-08-11 | Weisenfeld Michael S | Method of reducing weight in mammals |
| US5200183A (en) * | 1987-11-19 | 1993-04-06 | Oklahoma Medical Research Foundation | Recombinant bile salt activated lipases |
| US5308766A (en) * | 1989-08-29 | 1994-05-03 | The Regents Of The University Of California | Hydrolytic enzyme inhibitors/inactivators and methods for using same |
| US5362827A (en) * | 1986-09-08 | 1994-11-08 | Exxon Research & Engineering Co. | Solution process for preparation hydrophobically functionalized cationic polymers (C-2691) |
| US5376674A (en) * | 1990-02-26 | 1994-12-27 | Hoffman-La Roche Inc. | Oxetanone compounds containing proline and pharmaceutical compositions thereof |
| US5401498A (en) * | 1992-03-28 | 1995-03-28 | Hoechst Aktiengesellschaft | Pharmaceuticals comprising polyhydroxymethylene derivatives, process for their preparation and use |
| US5427919A (en) * | 1989-08-29 | 1995-06-27 | The Regents Of The University Of California | Hydrolytic enzyme inhibitors/inactivators and methods for using same |
| US5453282A (en) * | 1992-03-24 | 1995-09-26 | Kirin Beer Kabushiki Kaisha | Dietary lipid digestion-absorption inhibitory agents and ingesta |
| US5453429A (en) * | 1994-01-24 | 1995-09-26 | Rohm And Haas Company | Crosslinked anion exchange particles and method for producing the particles |
| US5474993A (en) * | 1994-06-14 | 1995-12-12 | Sterling Winthrop, Inc. | Lactam inhibitors of cholesterol esterase |
| US5484777A (en) * | 1989-04-20 | 1996-01-16 | Lange, Iii; Louis G. | Pancreatic cholesterol esterase inhibitor |
| US5569452A (en) * | 1993-08-31 | 1996-10-29 | Tsrl, Inc. | Pharmaceutical formulation having enhanced bile acid binding affinity |
| US5597810A (en) * | 1984-12-27 | 1997-01-28 | Hoffman; Allan S. | Method for reducing absorption of undesired lipids in the gastrointestinal tract |
| US5607669A (en) * | 1994-06-10 | 1997-03-04 | Geltex Pharmaceuticals, Inc. | Amine polymer sequestrant and method of cholesterol depletion |
| US5618530A (en) * | 1994-06-10 | 1997-04-08 | Geltex Pharmaceuticals, Inc. | Hydrophobic amine polymer sequestrant and method of cholesterol depletion |
| US5624963A (en) * | 1993-06-02 | 1997-04-29 | Geltex Pharmaceuticals, Inc. | Process for removing bile salts from a patient and compositions therefor |
| US5665348A (en) * | 1992-01-14 | 1997-09-09 | Hisamitsu Pharmaceutical Co, Inc. | Cholesterol-lowering drug |
| US5679717A (en) * | 1994-06-10 | 1997-10-21 | Geltex Pharmaceuticals, Inc. | Method for removing bile salts from a patient with alkylated amine polymers |
| US5703188A (en) * | 1993-06-02 | 1997-12-30 | Geltex Pharmaceuticals, Inc. | Process for removing bile salts from a patient and compositions therefor |
| US5750524A (en) * | 1994-08-25 | 1998-05-12 | Zeria Pharmaceutical Co., Ltd. | Remedy for hyperlipidemia |
| US5900475A (en) * | 1994-06-10 | 1999-05-04 | Geltex Pharmaceuticals, Inc. | Hydrophobic sequestrant for cholesterol depletion |
| US5900233A (en) * | 1997-10-16 | 1999-05-04 | Day; Charles E. | Epichlorohydrin and 1-(3-aminopropyl) imidazole copolymer and its use in treating irritable bowel syndrome |
| US6030953A (en) * | 1998-08-14 | 2000-02-29 | Hoffmann-La Roche Inc. | Pharmaceutical composition containing chitosan |
| US6299868B1 (en) * | 1999-07-14 | 2001-10-09 | Geltex Pharmaceuticals, Inc. | Fat-binding polymers |
| US6358522B1 (en) * | 1998-08-14 | 2002-03-19 | Hoffmann-La Roche Inc. | Pharmaceutical compositions containing lipase inhibitor |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1213397A (en) | 1980-10-20 | 1986-10-28 | Judith L. Page | Weight control with alkyl styrene polymers |
| EP0354948A1 (en) | 1988-02-12 | 1990-02-21 | DE ZAEPFFEL, Brigitte | Crosslinked hydrophilic copolymer for medical and paramedical use |
| JP3507523B2 (en) | 1993-05-12 | 2004-03-15 | 積水化学工業株式会社 | Carbohydrate absorption inhibitor |
-
1998
- 1998-10-05 US US09/166,453 patent/US6264937B1/en not_active Expired - Lifetime
-
1999
- 1999-01-04 CN CNA200510078190XA patent/CN1698647A/en active Pending
-
2002
- 2002-11-27 US US10/307,151 patent/US20030175236A1/en not_active Abandoned
Patent Citations (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3780171A (en) * | 1969-12-27 | 1973-12-18 | Merck Patent Gmbh | Ingestible polymeric compositions |
| US3923972A (en) * | 1971-10-12 | 1975-12-02 | Monsanto Co | Method of lowering blood cholesterol level |
| US4211765A (en) * | 1971-10-12 | 1980-07-08 | Monsanto Company | Method for controlling obesity |
| US4160826A (en) * | 1975-12-12 | 1979-07-10 | Laboratory Biochimici Fargal-Pharmasint S.P.A. | Inhibitor preparation for the absorption of lipids, based on diethylaminoethyldextran |
| US4265879A (en) * | 1977-09-13 | 1981-05-05 | Monsanto Company | Method for controlling blood triglycerides |
| US4218443A (en) * | 1979-01-15 | 1980-08-19 | Hoffmann-La Roche Inc. | Polyether ionophores as antiobesity and hypotriglyceridemic agents |
| US4302450A (en) * | 1979-01-15 | 1981-11-24 | Hoffmann-La Roche Inc. | Polyether ionophores as antiobesity and hypotriglyceridemic agents |
| US4432968A (en) * | 1980-10-20 | 1984-02-21 | The Dow Chemical Company | Weight control with fat imbibing polymers |
| US4598089A (en) * | 1983-06-22 | 1986-07-01 | Hoffmann-La Roche Inc. | Leucine derivatives |
| US5597810A (en) * | 1984-12-27 | 1997-01-28 | Hoffman; Allan S. | Method for reducing absorption of undesired lipids in the gastrointestinal tract |
| US5362827A (en) * | 1986-09-08 | 1994-11-08 | Exxon Research & Engineering Co. | Solution process for preparation hydrophobically functionalized cationic polymers (C-2691) |
| US4759923A (en) * | 1987-06-25 | 1988-07-26 | Hercules Incorporated | Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives |
| US5200183A (en) * | 1987-11-19 | 1993-04-06 | Oklahoma Medical Research Foundation | Recombinant bile salt activated lipases |
| US4959179A (en) * | 1989-01-30 | 1990-09-25 | Lever Brothers Company | Stabilized enzymes liquid detergent composition containing lipase and protease |
| US5089163A (en) * | 1989-01-30 | 1992-02-18 | Lever Brothers Company, Division Of Conopco, Inc. | Enzymatic liquid detergent composition |
| US5063210A (en) * | 1989-04-20 | 1991-11-05 | Lange Iii Louis G | Use of sulfated polysaccharides to decrease cholesterol and fatty acid absorption |
| US5484777A (en) * | 1989-04-20 | 1996-01-16 | Lange, Iii; Louis G. | Pancreatic cholesterol esterase inhibitor |
| US5427919A (en) * | 1989-08-29 | 1995-06-27 | The Regents Of The University Of California | Hydrolytic enzyme inhibitors/inactivators and methods for using same |
| US5308766A (en) * | 1989-08-29 | 1994-05-03 | The Regents Of The University Of California | Hydrolytic enzyme inhibitors/inactivators and methods for using same |
| US5567597A (en) * | 1989-08-29 | 1996-10-22 | The Regents Of The University Of California | Hydrolytic enzyme inhibitors/inactivators and methods for using same |
| US5376674A (en) * | 1990-02-26 | 1994-12-27 | Hoffman-La Roche Inc. | Oxetanone compounds containing proline and pharmaceutical compositions thereof |
| US5286481A (en) * | 1990-11-15 | 1994-02-15 | Weisenfeld Michael S | Method of reducing weight in mammals |
| US5137716A (en) * | 1990-11-15 | 1992-08-11 | Weisenfeld Michael S | Method of reducing weight in mammals |
| US5665348A (en) * | 1992-01-14 | 1997-09-09 | Hisamitsu Pharmaceutical Co, Inc. | Cholesterol-lowering drug |
| US5453282A (en) * | 1992-03-24 | 1995-09-26 | Kirin Beer Kabushiki Kaisha | Dietary lipid digestion-absorption inhibitory agents and ingesta |
| US5401498A (en) * | 1992-03-28 | 1995-03-28 | Hoechst Aktiengesellschaft | Pharmaceuticals comprising polyhydroxymethylene derivatives, process for their preparation and use |
| US5624963A (en) * | 1993-06-02 | 1997-04-29 | Geltex Pharmaceuticals, Inc. | Process for removing bile salts from a patient and compositions therefor |
| US5703188A (en) * | 1993-06-02 | 1997-12-30 | Geltex Pharmaceuticals, Inc. | Process for removing bile salts from a patient and compositions therefor |
| US5569452A (en) * | 1993-08-31 | 1996-10-29 | Tsrl, Inc. | Pharmaceutical formulation having enhanced bile acid binding affinity |
| US5453429A (en) * | 1994-01-24 | 1995-09-26 | Rohm And Haas Company | Crosslinked anion exchange particles and method for producing the particles |
| US5693675A (en) * | 1994-06-10 | 1997-12-02 | Geltex Pharmaceuticals Inc. | Alkylated amine polymers |
| US5618530A (en) * | 1994-06-10 | 1997-04-08 | Geltex Pharmaceuticals, Inc. | Hydrophobic amine polymer sequestrant and method of cholesterol depletion |
| US5679717A (en) * | 1994-06-10 | 1997-10-21 | Geltex Pharmaceuticals, Inc. | Method for removing bile salts from a patient with alkylated amine polymers |
| US5607669A (en) * | 1994-06-10 | 1997-03-04 | Geltex Pharmaceuticals, Inc. | Amine polymer sequestrant and method of cholesterol depletion |
| US5900475A (en) * | 1994-06-10 | 1999-05-04 | Geltex Pharmaceuticals, Inc. | Hydrophobic sequestrant for cholesterol depletion |
| US5474993A (en) * | 1994-06-14 | 1995-12-12 | Sterling Winthrop, Inc. | Lactam inhibitors of cholesterol esterase |
| US5750524A (en) * | 1994-08-25 | 1998-05-12 | Zeria Pharmaceutical Co., Ltd. | Remedy for hyperlipidemia |
| US5900233A (en) * | 1997-10-16 | 1999-05-04 | Day; Charles E. | Epichlorohydrin and 1-(3-aminopropyl) imidazole copolymer and its use in treating irritable bowel syndrome |
| US6030953A (en) * | 1998-08-14 | 2000-02-29 | Hoffmann-La Roche Inc. | Pharmaceutical composition containing chitosan |
| US6358522B1 (en) * | 1998-08-14 | 2002-03-19 | Hoffmann-La Roche Inc. | Pharmaceutical compositions containing lipase inhibitor |
| US6299868B1 (en) * | 1999-07-14 | 2001-10-09 | Geltex Pharmaceuticals, Inc. | Fat-binding polymers |
Also Published As
| Publication number | Publication date |
|---|---|
| US6264937B1 (en) | 2001-07-24 |
| CN1698647A (en) | 2005-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6264937B1 (en) | Fat-binding polymers | |
| PL193453B1 (en) | Lipase inhibiting polymers | |
| AU7967598A (en) | Polyallylamine polymers for treating hypercholesterolemia | |
| WO1998043653A1 (en) | Interpenetrating polymer networks for sequestration of bile acids | |
| JP2004535384A (en) | How to reduce serum glucose | |
| EP1404349B1 (en) | Fat-binding polymers | |
| JPH04298508A (en) | Compositions and methods for cholesterol suppression | |
| AU2002346034A1 (en) | Fat-binding polymers | |
| EP1043981B1 (en) | Fat-binding polymers combined with lipase inhibitors for the treatment of obesity | |
| US6726906B1 (en) | Fat-binding polymers | |
| AU774636B2 (en) | Fat-binding polymers, optionally combined with lipase inhibitors | |
| US7048917B1 (en) | Fat-binding polymers | |
| NZ516554A (en) | Fat-binding polymers, optionally combined with lipase inhibitors | |
| AU2005247010B2 (en) | Fat-binding polymers | |
| HK1081879A (en) | Fat-binding polymers | |
| MXPA00004329A (en) | Unsubstituted polydiallylamine for treating hypercholesterolemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: GENZYME CORPORATION, MASSACHUSETTS Free format text: MERGER;ASSIGNOR:GELTEX PHARMACEUTICALS, INC.;REEL/FRAME:014022/0197 Effective date: 20030327 |
|
| AS | Assignment |
Owner name: GELTEX PHARMACEUTICALS, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MANDEVILLE, W. HARRY, III;WHITESIDES, GEORGE M.;HOLMES-FARLEY, STEPHEN RANDALL;REEL/FRAME:018755/0576;SIGNING DATES FROM 19981203 TO 19981208 |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |